var title_f1_53_1872="Erosion incus";
var content_f1_53_1872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A retraction pocket cholesteatoma of the posterosuperior quadrant with erosion of the incus long process",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A retraction pocket cholesteatoma of the posterosuperior quadrant. The incus long process is eroded leaving the drum adherent to the stapes head (S). An effusion is present in the middle ear and squamous debris emanates from the attic (the pneumatized space just superior to the middle ear, also called the epitympanum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1872=[""].join("\n");
var outline_f1_53_1872=null;
var title_f1_53_1873="Thyroid cancer spine MRI";
var content_f1_53_1873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic thyroid cancer: MRI of the cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance image (MRI) of the cervical spine in a 67-year-old woman with a two year history of rib pain and a destructive lesion in her right seventh rib, which, on biopsy, revealed metastatic follicular thyroid cancer. MRI shows destruction of C2 (arrows). She was treated with total thyroidectomy, external beam radiation, radioiodine, and spinal stabilization. Five years later she developed more bone metastases, but there was no evidence of progression of the lesion in C2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James Brierley, MB, BS, MRCP, FRCR, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1873=[""].join("\n");
var outline_f1_53_1873=null;
var title_f1_53_1874="Patient information: Dermatitis (The Basics)";
var content_f1_53_1874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15391\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/11/40112\">",
"         Irritant contact dermatitis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/30/6626\">",
"         Patient information: Eczema (atopic dermatitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/28/29122\">",
"         Patient information: Pyoderma gangrenosum (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/38/32354\">",
"         Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/59/6068\">",
"         Patient information: Poison ivy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Dermatitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/dermatitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H478263872\">",
"      <span class=\"h1\">",
"       What is dermatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dermatitis is a type of skin rash that can happen after your skin touches something that irritates it or something you are allergic to.",
"     </p>",
"     <p>",
"      Things that irritate the skin can be found in products you use every day, such as soaps or cleansers. Some of the things that can cause skin allergies include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Certain medicines, perfumes, or cosmetics",
"       </li>",
"       <li>",
"        The metal in some kinds of jewelry",
"       </li>",
"       <li>",
"        Plants, such as poison ivy and poison oak",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes you can develop a rash the first time you touch something. But it is also possible to get a rash from something you have used before without any problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478263879\">",
"      <span class=\"h1\">",
"       What other symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a rash, your skin may be red, dry, itchy, or cracked (",
"      <a class=\"graphic graphic_picture graphicRef78270 \" href=\"UTD.htm?39/11/40112\">",
"       picture 1",
"      </a>",
"      ). If your rash is caused by an allergy, you might also have some swelling or blisters where you have the rash.",
"     </p>",
"     <p>",
"      Severe symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Widespread swelling",
"       </li>",
"       <li>",
"        Large blisters, oozing, or crusting of the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478263886\">",
"      <span class=\"h1\">",
"       What can I do to get rid of my dermatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid using or touching whatever might have caused your rash",
"       </li>",
"       <li>",
"        Protect your skin from anything that might irritate it or cause an allergy. For example, wear gloves if you need to work with harsh soaps.",
"       </li>",
"       <li>",
"        Try using soothing skin products to help with the itching and discomfort. Things that might help include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Unscented, thick moisturizing cream",
"       </li>",
"       <li>",
"        Anti-itch lotion or cream",
"       </li>",
"       <li>",
"        A special kind of bath called an oatmeal bath",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478263893\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if your rash does not go away within 2 weeks, or if it gets worse. Your doctor can help figure out what could be causing your rash.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478263900\">",
"      <span class=\"h1\">",
"       How are skin rashes treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might prescribe different treatments or medicines to help your rash. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Steroid creams and ointments",
"        </strong>",
"        &ndash; These medicines are different than the steroids athletes take to build muscle. They go on the skin, and they relieve itching and redness.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Steroid pills &ndash;",
"        </strong>",
"        You might need to take these for a short time if your rash is severe. But your doctor or nurse will want to take you off steroid pills as soon as possible. Even though these medicines help, they can also cause problems of their own.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Wet or damp dressings",
"        </strong>",
"        &ndash; These can be helpful for skin that is crusting or oozing. To use a wet or damp dressing, you will need to wear two layers of clothing. First, you put on a layer of damp cotton clothes over your rash. Then, you put on a layer of dry clothes on top of the damp ones. People who need these dressings often wear them at night when they sleep.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H478263907\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=see_link\">",
"       Patient information: Eczema (atopic dermatitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"       Patient information: Pyoderma gangrenosum (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=see_link\">",
"       Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=see_link\">",
"       Patient information: Poison ivy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/53/1874?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15391 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1874=[""].join("\n");
var outline_f1_53_1874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263872\">",
"      What is dermatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263879\">",
"      What other symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263886\">",
"      What can I do to get rid of my dermatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263893\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263900\">",
"      How are skin rashes treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H478263907\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/11/40112\">",
"      Irritant contact dermatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/59/6068?source=related_link\">",
"      Patient information: Poison ivy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=related_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1875="Rheumatic subcutaneous nodules";
var content_f1_53_1875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatic subcutaneous nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rheumatic subcutaneous nodules are usually located near tendons or over a bony surface or prominence. The overlying skin is not inflamed and typically can be moved over the nodules. The diameter varies from a few millimeters to one to two centimeters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Sidbury, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1875=[""].join("\n");
var outline_f1_53_1875=null;
var title_f1_53_1876="Inferior vena cava flow TR";
var content_f1_53_1876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inferior vena cava in tricuspid insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis view of the inferior vena cava (IVC) is obtained from the subcostal window (panel A); the hepatic veins (HV), and the entrance of the IVC into the right atrium (RA) are seen. Color flow Doppler (red) demonstrates retrograde systolic flow into the IVC and HV (panel B). Pulsed Doppler shows loss of normal systolic forward flow with exaggerated reversal of flow and an exaggerated V wave with inspiration (panel C). In addition to demonstrating systolic pulsations of the IVC, intavenous upper extremity saline contrast can be used detect retrograde systolic flow into the hepatic veins (panel D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1876=[""].join("\n");
var outline_f1_53_1876=null;
var title_f1_53_1877="Central line SC infra anat";
var content_f1_53_1877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External landmarks for the infraclavicular approach to the subclavian vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1877=[""].join("\n");
var outline_f1_53_1877=null;
var title_f1_53_1878="Granisetron: Patient drug information";
var content_f1_53_1878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Granisetron: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     see \"Granisetron: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/36/33349?source=see_link\">",
"     see \"Granisetron: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Granisol&trade;;",
"     </li>",
"     <li>",
"      Sancuso&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Granisetron Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Kytril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to granisetron or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry, healthy skin on the upper arm.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is given on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store patches in pouch until ready for use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12518 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1878=[""].join("\n");
var outline_f1_53_1878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177431\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019438\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019440\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019439\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019444\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019445\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019447\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019442\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019443\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019448\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019449\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=related_link\">",
"      Granisetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/36/33349?source=related_link\">",
"      Granisetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1879="Clinical manifestations, diagnosis, and treatment of non-acid reflux";
var content_f1_53_1879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of non-acid reflux",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Radu Tutuian, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Donald O Castell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1879/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/53/1879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent symptoms in patients with suspected gastroesophageal reflux disease (GERD) who have been treated with proton pump inhibitors (PPIs) can be due to a variety of causes. A subset of these patients has symptoms related to continued reflux of non-acidic material. Advances in technology to evaluate esophageal function have clarified the role of non-acid reflux in the pathogenesis of persistent esophageal symptoms. Two developments have converged over the past 25 years to unmask the presence and prevalence of non-acid GERD symptoms. The availability of proton pump inhibitors in the late 1980s provided the opportunity to achieve maximal acid suppression. The development of ambulatory combined impedance-pH monitoring allowed identification of non-acid reflux episodes and their temporal relation to symptoms.",
"   </p>",
"   <p>",
"    This topic review will summarize the clinical importance of non-acid reflux. A general approach to patients with suspected GERD who have persistent symptoms after taking PPIs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux (GER) represents the retrograde flow of gastric content into the esophagus. It occurs even in healthy individuals and is regarded as \"physiologic\" as long as it does not induce esophageal mucosal abnormalities or symptoms.",
"   </p>",
"   <p>",
"    Acid reflux is defined as the reflux of gastric contents with a pH &lt;4.0. Non-acid reflux is reflux of gastric contents with a pH &gt;4.0 (ie, above the threshold used by conventional pH monitoring to identify acid reflux).",
"   </p>",
"   <p>",
"    Experts have suggested a new definition of GER episodes that defines reflux with a pH of 4.0 to 7.0 as \"weakly acidic\" reflux, and GER with a pH above 7.0 \"weakly alkaline\" [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/1\">",
"     1",
"    </a>",
"    ]. However, given the low prevalence of \"weakly alkaline\" reflux episodes we separate GER episodes into acid and non-acid using a cutoff value of 4.0, thereby grouping \"weakly acidic\" and \"weakly alkaline\" reflux into \"non-acid\" reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of clinically relevant non-acid reflux is poorly understood.",
"   </p>",
"   <p>",
"    There are limited data on the prevalence of non-acid reflux episodes in patients with gastroesophageal reflux disease (GERD) whose symptoms are controlled with proton pump inhibitors (PPIs) (ie, the prevalence of asymptomatic non-acid reflux).",
"   </p>",
"   <p>",
"    It is the common consensus that 40 percent of the United States population experiences GERD symptoms. Approximately 40 percent of GERD patients have persistent gastroesophageal reflux (GER) symptoms on PPIs, and 40 percent of these have non-acid reflux associated with their symptoms (",
"    <a class=\"graphic graphic_figure graphicRef57581 \" href=\"UTD.htm?28/1/28703\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. One multicenter study of 168 patients with persistent symptoms on a PPI twice daily who underwent combined multichannel intraluminal impedance and pH (MII-pH) monitoring demonstrated that 37 percent had a positive symptoms index with non-acid reflux, while only 11 percent had a positive symptoms index for continued acid reflux (see",
"    <a class=\"local\" href=\"#H5204359\">",
"     'Multichannel intraluminal impedance and pH testing'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/2\">",
"     2",
"    </a>",
"    ]. A similar French-Belgian multicenter study in 71 patients on acid suppressive therapy found a positive symptom association probability (SAP) for non-acid reflux alone in 17 percent of patients, a positive SAP for acid and non-acid in 15 percent of patients, and a positive SAP for acid reflux only in 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1906876\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism by which non-acid reflux episodes produce symptoms remains uncertain. One possibility is that abrupt distension of the lower esophagus stimulates mechanoreceptors in the esophagus. There is also evidence that up to 30 percent of these patients may have a &ldquo;sensitive esophagus&rdquo; with normal total number of reflux episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients not taking acid suppressive medications (ie, off proton pump inhibitor [PPI] therapy), non-acid reflux occurs mainly in the postprandial period when gastric acid is buffered by the ingested food. The postprandial period is also prime time for gastroesophageal reflux as tLESRs occur more frequently following meal-induced gastric fundus distension. One study found that 6 to 16 percent of patients off PPI therapy have a positive symptom association probability (SAP) for non-acid reflux only underscoring the role of non-acid reflux in the pathogenesis of reflux symptoms in patients with erosive and non-erosive reflux disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proton pump inhibitors (PPIs) are potent gastric acid suppressants but do not affect structural and motility abnormalities at the gastroesophageal junction responsible for gastroesophageal reflux disease (GERD) (ie, hiatal hernias, decreased lower esophageal sphincter pressure, transient lower esophageal relaxations). Therefore, PPIs do not decrease reflux; they simply change the acidity of the refluxate. This is particularly true postprandially, when reflux and symptoms occur most frequently (",
"    <a class=\"graphic graphic_figure graphicRef76249 \" href=\"UTD.htm?38/58/39854\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1906793\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of non-acid reflux episodes do not cause symptoms. Patients with non-acid reflux may present with symptoms of refractory gastroesophageal reflux (GER) with heartburn (pyrosis), regurgitation, and cough. Of these, regurgitation and cough are the symptoms that have most frequently been associated with non-acid reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, whether extra-esophageal symptoms can truly be attributed to non-acid reflux is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 22 patients with chronic cough used 24-hour combined MII-pH monitoring to evaluate the relationship between non-acid reflux and cough [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/9\">",
"       9",
"      </a>",
"      ]. In this study, the majority of cough events (69 percent) occurred independently of reflux whereas 31 percent occurred within two minutes of a reflux episode. Only half of these (49 percent) were \"reflux cough\" sequences due to acid reflux (65 percent), and non-acid reflux (weakly acidic 29 percent, and weakly alkaline 6 percent).",
"     </li>",
"     <li>",
"      In another study, 50 patients with chronic cough underwent combined MII-pH monitoring while on acid suppressive therapy with a proton pump inhibitor (PPI) twice daily with or without an H2 receptor antagonist at bedtime [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/10\">",
"       10",
"      </a>",
"      ]. In this study, there was an association between cough and non-acid reflux in only 13 patients (26 percent). Patients with non-acid reflux associated with cough tended to be younger and were more likely to be male compared with those who had non-acid reflux that was not associated with cough.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-acid reflux is suspected in patients who present with one or a combination of gastroesophageal reflux (GER) symptoms and less than a complete response to treatment with twice daily proton pump inhibitor (PPI) therapy (given 30 minutes before breakfast and dinner). Combined multichannel intraluminal impedance and pH (MII-pH) monitoring is the reference standard for the diagnosis of non-acid reflux. The finding of a refluxate pH &gt;4 in a patient in whom at least one-half of the symptoms are associated with reflux is consistent with a diagnosis of non-acid reflux. Upper endoscopy is recommended in patients with alarm symptoms (dysphagia, anemia,",
"    <span class=\"nowrap\">",
"     hematemesis/melena,",
"    </span>",
"    or weight loss) and esophageal manometry is recommended in the evaluation of patients with dysphagia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5204359\">",
"    <span class=\"h2\">",
"     Multichannel intraluminal impedance and pH testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with persistent GER symptoms despite PPI therapy require multichannel intraluminal impedance and pH testing. Combined multichannel intraluminal impedance and pH (MII-pH) monitoring is based upon detection of changes in resistance to electrical currents. Liquids refluxing from the stomach into the esophagus are detected by MII-pH monitoring as decreases in the electrical resistance to alternating current (ie, impedance) progressing over time from distal to proximal (ie, retrograde bolus movement).",
"   </p>",
"   <p>",
"    The information provided by the pH electrode is used to classify reflux episodes into acid or non-acid (",
"    <a class=\"graphic graphic_figure graphicRef80772 \" href=\"UTD.htm?42/50/43814\">",
"     figure 3",
"    </a>",
"    ). Impedance-detected reflux episodes associated with a decline in pH from above to below 4.0 are considered acid, whereas impedance-detected reflux episodes during which the pH remains above 4.0 are considered to be non-acid.",
"   </p>",
"   <p>",
"    In addition to providing information on conventional pH parameters, combined MII-pH monitoring also provides information on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of acid and non-acid reflux episodes",
"     </li>",
"     <li>",
"      Number of liquid, gas, and mixed reflux episodes",
"     </li>",
"     <li>",
"      Proximal extent of reflux episodes",
"     </li>",
"     <li>",
"      Bolus contact time (ie, percentage of time bolus was present at 5 cm above the lower esophageal sphincter [LES])",
"     </li>",
"     <li>",
"      Acid contact time (ie, percentage of time pH &lt;4.0 at 5 cm above the LES)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed description of MII-pH is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259006447\">",
"    <span class=\"h3\">",
"     Symptom index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main parameter used to interpret MII-pH monitoring studies is the association of symptoms with gastroesophageal reflux episodes (acid and non-acid). To accomplish this, we favor using the symptom index (SI) representing the number of symptoms associated with reflux divided by the total number of symptoms recorded by a patient during the monitoring period expressed in percent. We prefer the SI over the symptom association probability (SAP) because it is an easily-calculated direct measure of",
"    <span class=\"nowrap\">",
"     reflux/symptom",
"    </span>",
"    relationship with a good specificity.",
"   </p>",
"   <p>",
"    Patients in whom at least one-half of the symptoms are associated with reflux (ie, SI &ge;50 percent) are considered to have symptomatic gastroesophageal reflux on PPI therapy (ie, positive test). By contrast, patients in whom less than one-half of symptoms are associated with reflux (ie, SI &lt;50 percent) are considered to have a negative study (ie, persistent symptoms on PPI therapy are due to causes other than gastroesophageal reflux). However, the validity of these cutoffs is still being determined.",
"   </p>",
"   <p>",
"    <strong>",
"     Upper endoscopy",
"    </strong>",
"    &nbsp;&mdash;&nbsp;The value of endoscopy in patients with refractory GER symptoms without alarm symptoms (dysphagia, odynophagia, anorexia, weight loss, and upper GI bleed) is limited. There is some evidence that if endoscopy is performed, biopsies assessing for dilated intercellular spaces might help to separate true refluxers from those who have functional heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Esophageal manometry",
"    </strong>",
"    &nbsp;&mdash;&nbsp;The value of esophageal manometry in refractory GERD is very limited and should be performed after MII-pH testing in patients with suspected achalasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10797961\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diseases that cause refractory gastroesophageal reflux (GER) symptoms of heartburn and regurgitation include esophageal hypersensitivity, functional heartburn, achalasia, severe esophagitis, and gastric stasis. These diseases are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\", section on 'Underlying mechanisms of PPI failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1907173\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, there have been few studies of specific therapy in the treatment of non-acid reflux and treatment approaches are evolving. Thus, treatment recommendations are based upon observational studies and clinical experience. In patients in whom lifestyle modifications fail to resolve symptoms, we suggest medical therapy. In patients with severe refractory symptoms, in whom lifestyle modifications fail to resolve symptoms, we suggest surgery. For patients who are not candidates for surgery, we suggest medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5204493\">",
"    <span class=\"h2\">",
"     Lifestyle modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with non-acid reflux should be counseled regarding lifestyle modifications that may improve symptoms. These include avoiding late and large meals, staying upright for at least three hours after a meal, weight loss, and sleeping with the head of the bed elevated and lying on the left side to decrease reflux. However, the efficacy of these measures to reduce non-acid reflux has not been formally investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5204500\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose symptoms fail to resolve with lifestyle changes should be treated with medical therapy. Studies have evaluated medications that reduce the rate of transient lower esophageal sphincter relaxation (TLESR) and thus the number of reflux episodes. In observational studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , a GABA-B agonist, decreases both acid and non-acid postprandial reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In a case-control study, patients with refractory gastroesophageal reflux (GER) symptoms treated with baclofen reported improvement in symptoms and postprandial reflux with regular dosing of baclofen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the drug crosses the blood-brain barrier, a variety of central nervous system (CNS)-related side effects may occur. They primarily include somnolence, confusion, dizziness, lightheadedness, drowsiness, weakness, and trembling. These side effects are an important limiting factor in the routine usage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    in clinical practice. We begin with 10 mg twice a day and increase the dosage slowly to 20 mg three times a day before meals, while carefully monitoring for side effects.",
"   </p>",
"   <p>",
"    A report of 10 patients found that a preparation of sodium alginate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    (Gaviscon&reg; Advance) given postprandially decreased the number of acid reflux episodes and distal esophageal acid exposure 5 cm above the LES (lower esophageal sphincter) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to treating symptomatic non-acid reflux is reducing the perception of these reflux episodes using visceral modulators. A double-blind, placebo-controlled study evaluated the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    20 mg daily versus placebo on esophageal symptoms in patients with hypersensitive esophagus (ie, positive symptom index in patients with normal upper GI endoscopy and normal distal esophageal acid exposure) on proton pump inhibitor (PPI) therapy. At the end of a six-month treatment period,",
"    <span class=\"nowrap\">",
"     24/39",
"    </span>",
"    (62 percent) of patients receiving citalopram 20 mg daily and",
"    <span class=\"nowrap\">",
"     12/36",
"    </span>",
"    (33 percent) receiving placebo reported complete disappearance of the predominant symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5204486\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundoplication has the potential to reduce non-acid reflux by strengthening anatomic antireflux mechanisms. However, there are limited data to support fundoplication for non-acid reflux. These include uncontrolled studies that have used subjective measures of success:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 15 patients off PPI therapy before and seven months after laparoscopic Nissen-Rossetti fundoplication found that laparoscopic fundoplication improved acid reflux parameters (percent time pH &lt;4 and DeMeester score) and the total number of impedance-detected episodes of both acid and non-acid reflux (",
"      <a class=\"graphic graphic_figure graphicRef60423 \" href=\"UTD.htm?26/0/26638\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study evaluated the response to antireflux surgery in 19 patients who underwent laparoscopic Nissen fundoplication for non-acid reflux detected on combined impedance-pH monitoring while on a PPI twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/18\">",
"       18",
"      </a>",
"      ]. Prior to surgery, 18 of the 19 patients had a positive symptom index for gastroesophageal reflux (GER) symptoms and reflux on acid suppressive therapy. At a mean follow-up of 14 months, 16 of 17 patients (94 percent) were asymptomatic or markedly improved. However, this study lacked a control arm, reflux was not objectively quantified after surgery, and was based on subjective endpoints of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fundoplication should only be considered in patients with no contraindications to surgery and by a skilled laparoscopic surgeon with experience in fundoplication.",
"   </p>",
"   <p>",
"    It is difficult to predict which patients will respond to fundoplication. A lack of response to a PPI has traditionally been a negative predictor for response to laparoscopic fundoplication. A retrospective review of 34 pediatric patients having fundoplication concluded that none of the reflux parameters detected on preoperative MII-pH testing predicted the outcome of anti-reflux surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1879/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link&amp;anchor=H31#H31\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\", section on 'Surgical treatments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link&amp;anchor=H22#H22\">",
"     \"Surgical management of gastroesophageal reflux in adults\", section on 'Laparoscopic Nissen fundoplication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-acid reflux is reflux of gastric contents with a pH &gt;4.0 (ie, above the threshold used by conventional pH monitoring to identify acid reflux). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-acid reflux is typically suspected in patients who present with one or a combination of potential symptoms of gastroesophageal reflux disease and have less than a complete response to treatment with twice daily high dose proton pump inhibitors (PPIs). (See",
"      <a class=\"local\" href=\"#H1906793\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combined multichannel intraluminal impedance and pH (MII-pH) monitoring is the reference standard for the diagnosis of non-acid reflux and can help distinguish non-acid reflux from other causes of persistent gastroesophageal reflux symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link&amp;anchor=H3#H3\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\", section on 'Underlying mechanisms of PPI failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There have been few studies of specific therapy in the treatment of non-acid reflux. Our approach is based mainly upon clinical observations.",
"      <br/>",
"      <br/>",
"      All patients with non-acid reflux should be counseled regarding lifestyle modifications that may improve symptoms. In patients who fail to respond to lifestyle changes, we suggest medical therapy prior to consideration of surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , while carefully monitoring for side effects.",
"      <br/>",
"      <br/>",
"      In patients with severe or refractory symptoms despite medical therapy, and in whom the diagnosis is confirmed by combined MII-pH monitoring, we suggest laparoscopic Nissen fundoplication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      We consider laparoscopic Nissen fundoplication only in patients with no contraindications to surgery and by a skilled laparoscopic surgeon with experience in fundoplication. Patients must also be counseled on the limited data supporting laparoscopic Nissen fundoplication and difficulty in predicting which patients will respond to fundoplication. We feel that an unequivocally positive symptom index is a presurgical requirement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"       \"Surgical management of gastroesophageal reflux in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link&amp;anchor=H22#H22\">",
"       \"Surgical management of gastroesophageal reflux in adults\", section on 'Laparoscopic Nissen fundoplication'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/1\">",
"      Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/2\">",
"      Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/3\">",
"      Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/4\">",
"      Iwakiri K, Kawami N, Sano H, et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol 2009; 44:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/5\">",
"      Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/6\">",
"      Savarino E, Tutuian R, Zentilin P, et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am J Gastroenterol 2010; 105:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/7\">",
"      Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/8\">",
"      Blonski W, Vela MF, Castell DO. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. J Clin Gastroenterol 2009; 43:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/9\">",
"      Sifrim D, Dupont L, Blondeau K, et al. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005; 54:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/10\">",
"      Tutuian R, Mainie I, Agrawal A, et al. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest 2006; 130:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/11\">",
"      Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/12\">",
"      Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/13\">",
"      Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/14\">",
"      Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/15\">",
"      Zentilin P, Dulbecco P, Savarino E, et al. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. Aliment Pharmacol Ther 2005; 21:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/16\">",
"      Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/17\">",
"      del Genio G, Tolone S, del Genio F, et al. Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008; 22:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/18\">",
"      Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1879/abstract/19\">",
"      Rosen R, Levine P, Lewis J, et al. Reflux events detected by pH-MII do not determine fundoplication outcome. J Pediatr Gastroenterol Nutr 2010; 50:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2244 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1879=[""].join("\n");
var outline_f1_53_1879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1906876\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1906793\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5204359\">",
"      Multichannel intraluminal impedance and pH testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259006447\">",
"      - Symptom index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10797961\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1907173\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5204493\">",
"      Lifestyle modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5204500\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5204486\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2244|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/1/28703\" title=\"figure 1\">",
"      Estimated prevalence of non-acid reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/58/39854\" title=\"figure 2\">",
"      GI reflux off and on acid suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/50/43814\" title=\"figure 3\">",
"      Reflux episodes identified by combined impedance-pH monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/0/26638\" title=\"figure 4\">",
"      Impedance-pH monitoring and laparoscopic Nissen fundoplication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1880="Moexipril: Drug information";
var content_f1_53_1880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moexipril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/32/6661?source=see_link\">",
"    see \"Moexipril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Univasc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 7.5 mg once daily (in patients",
"     <b>",
"      not",
"     </b>",
"     receiving diuretics), 1 hour prior to a meal",
"     <b>",
"      or",
"     </b>",
"     3.75 mg once daily (when combined with thiazide diuretics); maintenance dose: 7.5-30 mg/day in 1 or 2 divided doses 1 hour before meals",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose the same as adults; adjust for renal impairment. Tablet may be cut in half (3.75 mg) for starting therapy (see Renal Impairment).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F198281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;40 mL/minute: Patients may be cautiously placed on 3.75 mg once daily, then upwardly titrated to a maximum of 15 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 7.5 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Univasc&reg;: 7.5 mg, 15 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9536647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with thiazide diuretics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F198308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Moexipril may be confused with Monopril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Flushing, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, heartburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Reversible increases in creatinine or BUN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, upper respiratory infection, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, anemia, angioedema, arrhythmia, bronchospasm, cerebrovascular accident, chest pain, dyspnea, elevated LFTs, eosinophilic pneumonitis, hepatitis, hypercholesterolemia, MI, oliguria, orthostatic hypotension, palpitation, proteinuria, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to moexipril or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose), angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F198271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may delay and reduce peak serum levels. Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Take on an empty stomach 1 hour before or 2 hours after a meal. Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of moexipril (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6199025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if moexipril is excreted into breast milk. The manufacturer recommends that caution be exercised when administering moexipril to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F198261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Moexipril HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $138.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $145.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Univasc Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $312.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $327.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F198249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F198262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cardiotensin (PL);",
"     </li>",
"     <li>",
"      Femipres (IT);",
"     </li>",
"     <li>",
"      Fempress (AT, CH, DE);",
"     </li>",
"     <li>",
"      Moex (BG, CZ, DK, FR, HK, RU);",
"     </li>",
"     <li>",
"      Perdix (GB, IL);",
"     </li>",
"     <li>",
"      Tensotec (GR);",
"     </li>",
"     <li>",
"      Univasc (KP, PH, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (moexiprilat): 180 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Moexipril: 90%; Moexiprilat: 50% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Parent drug: Hepatic and via GI tract to moexiprilat, 1000 times more potent than parent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Moexiprilat: 13%; reduced with food (AUC decreased by ~40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Moexipril: 1 hour; Moexiprilat: 2-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (50%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636. Available at: file://www.circulationaha.org/cgi/content/full/110/5/588. Last accessed October 26, 2004.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, \"Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis EJ, Hunsicker LG, Bain RP, et al, &ldquo;The Effect of Angiotensin-Converting Enzyme Inhibition on Diabetic Nephropathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(20):1456-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/8413456/pubmed\" id=\"8413456\" target=\"_blank\">",
"        8413456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, \"Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/53/1880/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9661 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1880=[""].join("\n");
var outline_f1_53_1880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709145\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198301\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198279\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198280\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198281\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198251\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9536647\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198308\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198299\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198257\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198240\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299723\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198245\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198271\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198247\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198260\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198285\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6199025\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198261\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198259\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198249\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198262\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198239\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198256\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/32/6661?source=related_link\">",
"      Moexipril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1881="Trichomonas vaginalis";
var content_f1_53_1881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trichomonas vaginalis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Jack D Sobel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1881/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/53/1881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomonas vaginalis is the causative agent of trichomoniasis. It is the most common non-viral sexually transmitted infection worldwide and accounts for 4 to 35 percent of vaginitis diagnosed in symptomatic women presenting in primary care settings in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of trichomonas vaginalis infection in reproductive aged women in the US was illustrated by a study in which 3754 women aged 14 to 49 years self-collected vaginal swab specimens that were subsequently evaluated for the presence of T. vaginalis using polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall prevalence of T. vaginalis was 3.1 percent, and increased with age. Prevalence was highest in non-Hispanic black women (13.3 percent) and lowest in non-Hispanic white women (1.3 percent). The annual incidence in the United States has been estimated to be three to five million cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/2\">",
"     2",
"    </a>",
"    ]. [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/3\">",
"     3",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The responsible organism is the flagellated protozoan trichomonas vaginalis, which may be found in the vagina, urethra, and paraurethral glands of infected women. Other sites include cervix, bladder, and Bartholin glands. Humans are the only natural host of T. vaginalis. The incubation period is unknown; however, in vitro studies suggest an incubation period of 4 to 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although survival on fomites has been reported, trichomoniasis is virtually always sexually transmitted. Fomites have no proven role in transmission of trichomonas infection. Trichomoniasis is associated with a high prevalence of coinfection with other sexually transmitted diseases. The organism can be identified in 30 to 40 percent of the male sexual partners of infected women, although carriage in men is self-limited and transient (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Male partners'",
"    </a>",
"    below). Spermicidal agents such as nonoxynol-9 reduce the rate of transmission of trichomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women can acquire the disease from other women, but men do not usually transmit the infection to other men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91868841\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomoniasis in women ranges from an asymptomatic carrier state to a severe, acute, inflammatory disease. More than 50 percent of infected women are asymptomatic. Asymptomatic carriage can occur for prolonged periods of time, thus it is not necessarily possible to ascertain when or from whom the infection was acquired.",
"   </p>",
"   <p>",
"    Classic signs and symptoms include a purulent, malodorous, thin discharge (70 percent of cases) with associated burning, pruritus, dysuria, frequency, and dyspareunia. Postcoital bleeding can occur. The urethra is also infected in the majority of women. Symptoms may be worse during menstruation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/6\">",
"     6",
"    </a>",
"    ]. The classically described green, frothy, foul-smelling discharge is found in fewer than 10 percent of symptomatic women.",
"   </p>",
"   <p>",
"    Physical examination often reveals erythema of the vulva and vaginal mucosa; the classic green-yellow frothy discharge is observed in 10 to 30 percent of affected women. Punctate hemorrhages may be visible on the vagina and cervix (\"strawberry cervix,\" 2 percent of cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9535475\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;T vaginalis infection in men is asymptomatic in 75 percent of cases and often transient (spontaneous resolution within 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Symptoms, when present (&lt;10 percent of cases), are the same as those for urethritis from any cause and consist of a clear or mucopurulent urethral discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONSEQUENCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9535531\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active trichomoniasis is a risk factor for development of post-hysterectomy cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/9\">",
"     9",
"    </a>",
"    ]. Untreated vaginal infection may progress to urethritis or cystitis. Another concern is that the infection appears to facilitate transmission of the human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A history of trichomoniasis has been associated with an increased risk of future tubal infertility and cervical neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/9,13-16\">",
"     9,13-16",
"    </a>",
"    ]. In a study of 696 African women attending a rural sexually transmitted disease clinic, trichomoniasis was associated with an increased risk of clinical pelvic inflammatory disease in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of trichomoniasis are potentially important in pregnant women in whom infection is associated with a 30 percent increase in premature rupture of the membranes and preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/18\">",
"     18",
"    </a>",
"    ]. Moreover, treatment of asymptomatic infection does not reduce these complications (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Pregnancy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants born to infected mothers may contract infection during delivery. Signs and symptoms in neonates may include fever, respiratory problems, urinary tract infection, nasal discharge, and, in girls, vaginal discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Treatment of asymptomatic infants is not necessary as spontaneous resolution will occur when estrogen levels wane to normal prepubescent levels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9535482\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications include prostatitis, balanoposthitis, epididymitis, infertility, and prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H29#H29\">",
"     \"Risk factors for prostate cancer\", section on 'Trichomonas vaginalis infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of trichomonas is based on laboratory testing, as described below. As with other types of vaginitis, none of the clinical features of trichomonas vaginitis is sufficiently sensitive or specific to allow a diagnosis based upon signs and symptoms alone (",
"    <a class=\"graphic graphic_table graphicRef68759 \" href=\"UTD.htm?38/29/39388\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The general diagnostic approach to women with vaginal discharge is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microscopy and pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of motile trichomonads on wet mount is diagnostic of infection, but this occurs in only 60 to 70 percent of culture-confirmed cases (",
"    <a class=\"graphic graphic_picture graphicRef71667 \" href=\"UTD.htm?41/1/42014\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/26\">",
"     26",
"    </a>",
"    ]. The motion is jerky and spinning; organisms remain motile for 10 to 20 minutes after collection of the sample. Other findings that are almost invariably present with trichomonas infection, but nondiagnostic, include an elevated vaginal pH (&gt;4.5) and an increase in polymorphonuclear leukocytes on saline microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture on Diamond's medium has a high sensitivity (95 percent) and specificity (&gt;95 percent) and should be considered in patients with elevated vaginal pH, increased numbers of polymorphonuclear leukocytes and an absence of motile trichomonads and clue cells on wet mount; or when microscopy is unavailable or yields unreliable results. This test is not readily available and takes up to seven days to obtain a result. Alternatively, a commercial \"In Pouch\" T vaginalis culture system takes up to three days to obtain results and is readily available (BioMed Diagnostics, White City, Oregon).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rapid antigen and nucleic acid amplification tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnostic kits can be useful in areas of high prevalence where microscopy or culture is not available (ie, sexually transmitted disease (STD) clinics and inner city clinics serving the uninsured are high prevalence sites). The following tests are performed at the point of care and are commercially available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      APTIMA Trichomonas vaginalis assay (Gen-Probe) &ndash; The APTIMA Trichomonas vaginalis assay uses target capture and transcription mediated amplification to detect species specific ribonucleic acid (RNA), including N gonorrhoeae, C trachomatis and T vaginalis on a vaginal swab or urine specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/27\">",
"       27",
"      </a>",
"      ]. Reported sensitivity ranges from 97 to 100 percent and specificity ranges from 87 to 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28-31\">",
"       28-31",
"      </a>",
"      ]. The APTIMA TV assay has demonstrated superior performance in side-by-side comparisons with other diagnostic methods in all patient populations and specimen types tested (vaginal discharge, urine).",
"     </li>",
"     <li>",
"      AFFIRM VP III - The Affirm VP III Microbial Identification System (Becton Dickinson) test uses a nucleic acid probe on a vaginal swab specimen. Results are available in 45 minutes. Although sensitivity and specificity have been reported to exceed 95 percent, in side-by-side testing, this method was inferior to target capture and transcription mediated amplification (sensitivity 63.4 versus 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/29\">",
"       29",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      OSOM - The OSOM Trichomonas Rapid Test (Genzyme) uses an immunochromatographic technology on a vaginal swab specimen. Results are available in 10 minutes. It has sensitivity of 88.3 percent and specificity of 98.8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The excellent performance characteristics of these tests are illustrated by the following comparative studies, which compare performance of traditional and rapid testing methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study recruited 330 sexually active adolescent females seeking care at a teen health clinic or emergency department and tested them for T. vaginalis using the four test methods discussed above: wet mount, culture (InPouch TV), rapid antigen testing (OSOM TV), and transcription-mediated amplification testing (APTIMA TV) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/33\">",
"       33",
"      </a>",
"      ]. The sensitivities of the four methods were 65, 96, 90, and 98 percent, respectively.",
"     </li>",
"     <li>",
"      Another study enrolled 296 female and 298 male subjects seeking care at a sexually transmitted disease clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/27\">",
"       27",
"      </a>",
"      ]. Specimens from each subject were tested for trichomoniasis using transcription-mediated amplification (APTIMA TV), wet mount microscopy, culture, and PCR tests. The subject was diagnosed with trichomoniasis if any of these tests was positive. In women, vaginal swab APTIMA TV was more sensitive than wet mount or culture (96.6 versus 54.6 and 75.0 percent, respectively). In men, urethral swab APTIMA TV was more sensitive than culture or PCR (95.2 versus 28.6 and 54.8 percent, respectively).",
"     </li>",
"     <li>",
"      In a third study, specimens were retrieved consecutively from 766 patients with vaginal complaints",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with histories suggestive of a sexually transmitted disease and tested by both the AFFIRM and the APTIMA trichomonas vaginalis assays [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/29\">",
"       29",
"      </a>",
"      ]. Overall, 5.1 percent of patients were positive for T vaginalis (defined as a specimen with two positive test results for T vaginalis by two different molecular assays). The APTIMA assay was statistically more sensitive than the AFFIRM assay (100 versus 63.4 percent); specificity was similar (APTIMA 100 percent, AFFIRM 99.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Amplicor (Roche) is a PCR assay for detection of N gonorrhoeae and C trachomatis that has been modified to detect T vaginalis in",
"    <span class=\"nowrap\">",
"     vaginal/endocervical",
"    </span>",
"    swabs or urine; sensitivity and specificity are 88 to 97 percent and 98 to 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/34\">",
"     34",
"    </a>",
"    ]. It is not commercially available, but has been cleared by the United States Food and Drug Administration (FDA). NuSwab VG is a nucleic acid amplification single specimen assay for the detection of trichomoniasis, bacterial vaginosis and vulvovaginal candidiasis that has also been cleared by the FDA, but not yet commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomonads are sometimes reported as an incidental finding on conventional Papanicolaou (Pap) smears. Conventional Pap smears are inadequate for diagnosis of trichomoniasis because this technique has a sensitivity of only 51 to 63 percent and false positive results are common (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/35\">",
"     35",
"    </a>",
"    ]. This makes the positive predictive value very poor in a low prevalence population. Thus, Pap smear should not be used to diagnose trichomoniasis. Asymptomatic women with trichomonads identified on conventional Pap smear should be evaluated by wet mount, or culture or rapid antigen test if the wet mount is negative, and should not be treated until the diagnosis is confirmed.",
"   </p>",
"   <p>",
"    By comparison, the reliability of liquid-based cervical cytology appears to be higher. One study performed both liquid-based cervical cytology and culture for T. vaginalis on 203 consecutive women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/36\">",
"     36",
"    </a>",
"    ]. Forty-four women had a positive culture and 28 women had a positive liquid-based smear for trichomonads. Although the sensitivity of liquid-based smears for trichomonas infection was low (61 percent), specificity was high (99 percent), resulting in a false positive rate of only 1 percent. Thus, although liquid-based cervical cytology is not a sensitive test for diagnosis of trichomoniasis, we feel treatment of asymptomatic women with trichomonads noted on liquid-based cervical cytology is a reasonable approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9535522\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only reliable test to diagnose trichomonas in the male is PCR testing of first fraction urine or a urethral swab, which is not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/27\">",
"     27",
"    </a>",
"    ]; other tests, such as saline microscopy of a urethral swab, have low sensitivity and are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to screening for T. vaginalis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening for sexually transmitted infections\", section on 'Trichomoniasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be instructed to avoid intercourse until they and their partners have completed treatment and are asymptomatic, which generally takes about a week. After single dose therapy or treatment of asymptomatic patients, the couple should abstain from intercourse until",
"    <strong>",
"     both",
"    </strong>",
"    partners have waited at least seven days since taking the last antibiotic dose. There are no studies on how long trichomonads remain viable after treatment is initiated or completed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonpregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated in all nonpregnant women diagnosed with trichomonas vaginitis, even if asymptomatic. The rationale for treatment of asymptomatic women is that if left untreated, up to one-third become symptomatic within six months and they continue to transmit the infection to sexual partners while untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21057167\">",
"    <span class=\"h3\">",
"     5-nitroimidazole drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-nitroimidazole drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    ) are the only class of drugs that provide curative therapy of trichomoniasis. Most strains of T. vaginalis are highly susceptible to these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/37\">",
"     37",
"    </a>",
"    ]. Randomized clinical trials of these drugs have generally reported cure rates of 90 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Therapy with drugs other than 5-nitroimidazoles is an option, but cure rates are low (&le;50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend treatment with a single oral dose of 2 grams (four 500 mg tablets) of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28,40\">",
"     28,40",
"    </a>",
"    ]. Tinidazole was significantly more effective than metronidazole in several randomized trials; however, most of these trials were subject to bias since outcome was assessed by clinicians who were not blinded to the patient's treatment group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/40\">",
"     40",
"    </a>",
"    ]. Cure rates with tinidazole are considered comparable to those of metronidazole, but the drug is better tolerated.",
"   </p>",
"   <p>",
"    An alternative multidose regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg orally twice a day for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28\">",
"     28",
"    </a>",
"    ]. There is no FDA approved multiple dose regimen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    . Similar cure rates are obtained with single and multiple dose regimens (cure rate for single dose: 82 to 88 percent; cure rate for multiple dose: 85 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/38,40,43\">",
"     38,40,43",
"    </a>",
"    ]. The advantages of single-dose therapy include better compliance, a shorter period of alcohol avoidance, and possibly decreased Candida superinfection (although there is no evidence of decreased Candida superinfection). However, side effects (eg, nausea, vomiting, headache, metallic taste, dizziness) appear to be dose related and occur less frequently with the lower doses of multiple dose, prolonged therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral is preferred to vaginal therapy since systemic administration achieves therapeutic drug levels in the urethra and periurethral glands, which serve as endogenous reservoirs of organisms that can cause recurrence. Cure rates for vaginal therapy are &le;50 percent, which is significantly lower than with oral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28,40\">",
"     28,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be advised to not consume alcohol for 24 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    treatment and 72 hours after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    treatment because of the possibility of a disulfiram-like (Antabuse effect) reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21057085\">",
"    <span class=\"h3\">",
"     Allergy to 5-nitroimidazole drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the low efficacy of any drug other than the 5-nitroimidazole drugs (see",
"    <a class=\"local\" href=\"#H21057167\">",
"     '5-nitroimidazole drugs'",
"    </a>",
"    above), we suggest that patients with allergies to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    be referred for desensitization rather than using an alternative class of drugs. Desensitization is very effective: in one series, all 15 women who underwent desensitization subsequently eradicated their infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119293052\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up is unnecessary for women who become asymptomatic after treatment or who were initially asymptomatic, given the high efficacy of 5-nitroimidazole drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Male partners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of male partners is indicated because maximal cure rates in affected women are achieved when their male sexual partners are treated simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/45\">",
"     45",
"    </a>",
"    ]. It is not mandatory to identify the organism in a male partner before treating him (ie, Expedited Partner Therapy), given the high rate of concurrent carriage (30 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/8\">",
"     8",
"    </a>",
"    ]), difficulty of diagnosis in males, lower compliance when the partner is asked to visit his health care provider, and the convenience, low morbidity, and low cost of empiric treatment. Antimicrobial treatment of male partners is identical to therapy of non-pregnant females, with preference for single dose regimens to ensure compliance (single oral dose of 2 grams of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ). Neither partner should resume intercourse until both partners have completed treatment, otherwise reinfection can occur.",
"   </p>",
"   <p>",
"    Ideally, however, sexual partners should be referred for diagnostic evaluation because concurrent sexually transmitted infections, such as chlamydia and gonorrhea, are common and need to be diagnosed and treated as well, if present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, if the female has been diagnosed with chlamydia or gonorrhea, Expedited Partner Therapy (EPT) is also an option for these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of men with urethritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is the drug of choice for treatment of symptomatic trichomoniasis in pregnancy. Some clinicians avoid its use in the first trimester because it crosses the placenta, thus there is a potential for teratogenicity. In addition, the drug is mutagenic in bacteria and carcinogenic in mice. However, meta-analysis has not found any relationship between metronidazole exposure during the first trimester of pregnancy and birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/48\">",
"     48",
"    </a>",
"    ]. The Centers for Disease Control and Prevention no longer discourage the use of metronidazole in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In pregnant women, some clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg twice daily for five to seven days to the 2 g single dose regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/50\">",
"     50",
"    </a>",
"    ] because of the lower frequency of side effects in women who already have a high prevalence of nausea, but both regimens are acceptable.",
"   </p>",
"   <p>",
"    We suggest not treating asymptomatic infections during pregnancy because randomized trials have shown that it does not prevent, and in some trials even increased, the risk of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/19,51\">",
"     19,51",
"    </a>",
"    ]. This was best illustrated in a randomized trial of 617 women with culture proven asymptomatic infection at 16 to 23 weeks of gestation who were randomly assigned to receive either two 2 g doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or placebo 48 hours apart [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/19\">",
"     19",
"    </a>",
"    ]. All women were retreated with the same regimen at 24 to 29 weeks of gestation. The major findings from this trial were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichomonas resolved in 93 percent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      treated women and 35 percent of the placebo group.",
"     </li>",
"     <li>",
"      The rate of preterm birth was significantly higher in treated than control women (19 versus 11 percent, RR 1.8; 95% CI 1.2-2.7), primarily related to an increased frequency of spontaneous preterm labor (10.2 versus 3.5 percent, RR 3.0; 95% CI 1.5-5.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased risk of preterm delivery was unexpected. The authors and others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/52\">",
"     52",
"    </a>",
"    ] have speculated that use of twice the standard single 2 g",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    dose might have disturbed colonization of normal vaginal flora, thus enhancing the potential for preterm labor. Since more extensive culturing was not performed, the presence of other infections was not determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of spontaneous preterm birth\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic women may opt to undergo treatment after 37 weeks to prevent perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative management of symptomatic infections is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    1 percent cream inserted vaginally (preferably at bedtime) for seven consecutive days. This often results in symptomatic relief, but not eradication of the organisms. There is little information on the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    in pregnancy; therefore, we do not suggest its use.",
"   </p>",
"   <p>",
"    Treatment of sexual partners is indicated. Reinfection of treated partners of untreated women can be minimized by avoidance of sexual intercourse or use of condoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5937603\">",
"    <span class=\"h3\">",
"     Breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;When indicated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is used for treatment of infection in neonates. There are no human data supporting an association between metronidazole use and cancer; however, an association with carcinogenesis in rodents has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/53\">",
"     53",
"    </a>",
"    ]. Outcomes data of maternal metronidazole use did not show a significant increase in adverse events compared to use of other antimicrobials, although a cohort study found a nonsignificant trend toward more loose stools and more candidal colonization in metronidazole-exposed infants. Since the relative infant dose of metronidazole is high (29 percent) with maternal administration of the 2 g one-time dose, a cautious approach for mothers receiving this dose is to express and discard their milk for 12 to 24 hours to allow excretion of the drug. In mothers using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    , the Centers for Disease Control and Prevention (CDC) suggests interrupting breastfeeding for three days after the last dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3045469\">",
"    <span class=\"h2\">",
"     HIV-positive women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment recommendations for trichomoniasis have been based on studies conducted in HIV-negative persons. There is some evidence that HIV-positive women should receive longer treatment. In a randomized trial where HIV-positive women with culture confirmed trichomonas vaginalis were assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    2 g single dose or metronidazole 500 mg twice per day for seven days, single dose therapy was less effective than multiple-day therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/54\">",
"     54",
"    </a>",
"    ]. The 7-day treatment group had a lower rate of positive cultures 6 to 12 days after treatment completion (8.5 percent",
"    <span class=\"nowrap\">",
"     [11/130",
"    </span>",
"    women] versus 16.8 percent",
"    <span class=\"nowrap\">",
"     [21/125",
"    </span>",
"    women]; RR 0.5, 95% CI 0.25-1.00) and at 3 months (11 percent",
"    <span class=\"nowrap\">",
"     [8/73",
"    </span>",
"    women] versus 24.1 percent",
"    <span class=\"nowrap\">",
"     [19/79",
"    </span>",
"    women]; RR 0.46, 95% CI 0.21-0.98). Of note, all women were given 2 g metronidazole doses to deliver to their sex partners. &nbsp;",
"   </p>",
"   <p>",
"    Another study reported a high prevalence of bacterial vaginosis in",
"    <span class=\"nowrap\">",
"     HIV-positive/trichomonas-positive",
"    </span>",
"    women and observed an association between the presence of bacterial vaginosis and early failure of single dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    treatment of trichomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the 2010 CDC STD guidelines did not recommend more prolonged therapy for HIV positive women, it may be prudent to prescribe a seven-day course of therapy, given subsequent publication of additional data on these cases. However, more studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Refractory cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of treatment failure are noncompliance and reinfection. Compliance is enhanced with single dose therapy. Reinfection is unlikely if the partner was treated concurrently or sexual intercourse was avoided until both partners completed treatment.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) recommendation for therapy of recurrent trichomoniasis after failure of a single 2 g dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is to give metronidazole 500 mg twice daily for seven days (total dose 7 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/28\">",
"     28",
"    </a>",
"    ]. If this regimen fails,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    or metronidazole is administered at a dose of 2 g per day for five days (total dose 10 g). These regimens can be effective in patients with low levels of metronidazole resistance, which was noted in 4 percent of T. vaginalis isolates of women attending STD clinics in six cities in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If this fails, the CDC recommends in vitro culture and drug susceptibility testing (available from the CDC Division of STD Prevention, telephone 404-718-4141) and referral to a specialist. Therapeutic options include maximum tolerated doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , or preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    (2 to 4 g daily in divided doses) for 14 days. Considerable success with tinidazole in refractory disease has been reported although the optimal dose has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Cross resistance to tinidazole is frequent, but not inevitable [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Patients with high level metronidazole resistance are usually successfully treated by prolonged and high dose tinidazole therapy. High dose tinidazole has a better safety profile and is better tolerated than high dose metronidazole.",
"   </p>",
"   <p>",
"    Case reports have described successful use of nimorazole, ornidazole, niridazole, furazolidone, and hamycin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/7\">",
"     7",
"    </a>",
"    ], whereas a trial of nitazoxanide in three women with difficult to treat trichomonas vaginitis reported lack of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/61\">",
"     61",
"    </a>",
"    ]. Rare patients who do not have a response to nitroimidazoles have been treated with topical paromomycin (250 mg daily for two weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/62\">",
"     62",
"    </a>",
"    ]. Paromomycin is not available commercially in the United States as a cream and has to be made up by a compounding pharmacy. Little is known about this preparation. Severe local side effects (pain, mucosal ulceration) can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1881/abstract/63\">",
"     63",
"    </a>",
"    ]. We do not recommend using this medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acquiring infection can be reduced by consistent use of condoms and limiting the number of sexual partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=see_link\">",
"       \"Patient information: Trichomoniasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trichomoniasis is virtually always sexually transmitted. It is associated with a high prevalence of coinfection with other sexually transmitted diseases and can be identified in 30 to 40 percent of the male sexual partners of infected women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some possible consequences of trichomonas infection in women include pelvic inflammatory disease, post-hysterectomy cellulitis, and preterm birth; some possible consequences in men include prostatitis, infertility, and prostate cancer. Trichomonas infection in women appears to increase the risk of sexual acquisition of the human immunodeficiency virus (HIV). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations in women range from an asymptomatic carrier state to a severe, acute, inflammatory disease. Signs and symptoms include a purulent, malodorous, thin discharge with associated burning, pruritus, dysuria, frequency, and dyspareunia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic carriage can occur for prolonged periods of time, thus it is not necessarily possible to ascertain when or from whom the infection was acquired. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      None of the clinical features of trichomonas vaginitis is sufficiently sensitive or specific to allow a diagnosis based upon signs and symptoms alone. The presence of motile trichomonads on wet mount is diagnostic of infection, but this occurs in only 50 to 70 percent of culture-confirmed cases (",
"      <a class=\"graphic graphic_picture graphicRef71667 \" href=\"UTD.htm?41/1/42014\">",
"       picture 1",
"      </a>",
"      ). We suggest culture in patients with suggestive clinical findings (eg, elevated vaginal pH, increased numbers of polymorphonuclear leukocytes and an absence of motile trichomonads and clue cells on wet mount) or when microscopy is unavailable or unreliable. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several rapid antigen tests are now available for diagnosis of trichomonas vaginalis and can be used as an alternative to culture. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rapid antigen and nucleic acid amplification tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of trichomoniasis is indicated to relieve symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prevent transmission to sexual partners. We recommend a single oral dose of a 5-nitroimidazole drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      ) for nonpregnant women (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Single dose therapy is more convenient and is as effective as multiple dose therapy. Oral administration is more effective than vaginal administration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonpregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sexual partners of infected women be referred for evaluation of trichomoniasis and concurrent sexually transmitted infections rather than empirically treated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Male partners'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not treating asymptomatic trichomoniasis in pregnant women given the potentially increased risk of preterm birth associated with antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest treatment of symptomatic women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest increasing the dose and duration of medication in refractory cases (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Refractory cases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be instructed to avoid intercourse until they and their partners have completed treatment and are asymptomatic, which generally takes about a week. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/1\">",
"      Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004; 291:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/2\">",
"      Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007; 45:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/3\">",
"      Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol 2012; 50:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/4\">",
"      Hesseltine, H. Experimental human vaginal trichomoniasis. J Infect Dis 1942; 71:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/5\">",
"      d'Oro LC, Parazzini F, Naldi L, La Vecchia C. Barrier methods of contraception, spermicides, and sexually transmitted diseases: a review. Genitourin Med 1994; 70:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/6\">",
"      Heine P, McGregor JA. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol 1993; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/7\">",
"      Cudmore SL, Delgaty KL, Hayward-McClelland SF, et al. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev 2004; 17:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/8\">",
"      Se&ntilde;a AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007; 44:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/9\">",
"      Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol 1990; 163:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/10\">",
"      Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/11\">",
"      Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998; 351:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/12\">",
"      McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/13\">",
"      Soper D. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol 2004; 190:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/14\">",
"      Grodstein F, Goldman MB, Cramer DW. Relation of tubal infertility to history of sexually transmitted diseases. Am J Epidemiol 1993; 137:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/15\">",
"      El-Shazly AM, El-Naggar HM, Soliman M, et al. A study on Trichomoniasis vaginalis and female infertility. J Egypt Soc Parasitol 2001; 31:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/16\">",
"      Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol 1994; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/17\">",
"      Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002; 34:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/18\">",
"      Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/19\">",
"      Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/20\">",
"      Smith LM, Wang M, Zangwill K, Yeh S. Trichomonas vaginalis infection in a premature newborn. J Perinatol 2002; 22:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/21\">",
"      Temesv&aacute;ri P, Kerekes A, Tege A, Szarka K. Demonstration of Trichomonas vaginalis in tracheal aspirates in infants with early respiratory failure. J Matern Fetal Neonatal Med 2002; 11:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/22\">",
"      Hoffman DJ, Brown GD, Wirth FH, et al. Urinary tract infection with Trichomonas vaginalis in a premature newborn infant and the development of chronic lung disease. J Perinatol 2003; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/23\">",
"      Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg 2008; 78:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/24\">",
"      Hammill HA. Trichomonas vaginalis. Obstet Gynecol Clin North Am 1989; 16:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/25\">",
"      W&oslash;lner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA 1989; 261:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/26\">",
"      Krieger JN, Tam MR, Stevens CE, et al. Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA 1988; 259:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/27\">",
"      Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009; 200:188.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/28\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/29\">",
"      Andrea SB, Chapin KC. Comparison of Aptima Trichomonas vaginalis transcription-mediated amplification assay and BD affirm VPIII for detection of T. vaginalis in symptomatic women: performance parameters and epidemiological implications. J Clin Microbiol 2011; 49:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/30\">",
"      Chapin K, Andrea S. APTIMA&reg; Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens. Expert Rev Mol Diagn 2011; 11:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/31\">",
"      Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011; 49:4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/32\">",
"      Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of Trichomonas vaginalis in vaginal specimens. J Clin Microbiol 2005; 43:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/33\">",
"      Huppert JS, Mortensen JE, Reed JL, et al. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 2007; 45:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/34\">",
"      Van Der Pol B, Kraft CS, Williams JA. Use of an adaptation of a commercially available PCR assay aimed at diagnosis of chlamydia and gonorrhea to detect Trichomonas vaginalis in urogenital specimens. J Clin Microbiol 2006; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/35\">",
"      Wiese W, Patel SR, Patel SC, et al. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 2000; 108:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/36\">",
"      Lara-Torre E, Pinkerton JS. Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear. Am J Obstet Gynecol 2003; 188:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/37\">",
"      Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev 2004; 17:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/38\">",
"      Hager WD, Brown ST, Kraus SJ, et al. Metronidazole for vaginal trichomoniasis. Seven-day vs single-dose regimens. JAMA 1980; 244:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/39\">",
"      Manorama HT, Shenoy DR. Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole. J Int Med Res 1978; 6:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/40\">",
"      Forna F, G&uuml;lmezoglu AM. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2003; :CD000218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/41\">",
"      Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994; 170:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/42\">",
"      duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/43\">",
"      Thin RN, Symonds MA, Booker R, et al. Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis. Br J Vener Dis 1979; 55:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/44\">",
"      Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008; 198:370.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/45\">",
"      Lossick JG. Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis 1990; 12 Suppl 6:S665.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. US Department of Health and Human Services; Atlanta, GA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/47\">",
"      Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: a randomized controlled trial. Sex Transm Dis 2006; 33:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/48\">",
"      Caro-Pat&oacute;n T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/49\">",
"      Centers for Disease Control and Prevention, Workowsk,i KA, Berman, SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/50\">",
"      National guideline for the management of Trichomonas vaginalis. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/51\">",
"      Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005; 105:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/52\">",
"      Carey JC, Klebanoff MA. Is a change in the vaginal flora associated with an increased risk of preterm birth? Am J Obstet Gynecol 2005; 192:1341.",
"     </a>",
"    </li>",
"    <li>",
"     Lactmed. Available at file://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~R2NQWq:2. (Accessed on January 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/54\">",
"      Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/55\">",
"      Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011; 87:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/56\">",
"      Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012; 18:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/57\">",
"      Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001; 33:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/58\">",
"      Subramanian C, Sobel JD. A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated. J Low Genit Tract Dis 2011; 15:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/59\">",
"      Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006; 50:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/60\">",
"      Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis--an emerging problem. N Engl J Med 1999; 341:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/61\">",
"      Dan M, Sobel JD. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007; 34:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/62\">",
"      Nyirjesy P, Weitz MV, Gelone SP, Fekete T. Paromomycin for nitroimidazole-resistant trichomonosis. Lancet 1995; 346:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1881/abstract/63\">",
"      Poppe WA. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol 2001; 96:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5453 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1881=[""].join("\n");
var outline_f1_53_1881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91868841\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9535475\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9535531\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9535482\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microscopy and pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rapid antigen and nucleic acid amplification tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9535522\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonpregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21057167\">",
"      - 5-nitroimidazole drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21057085\">",
"      - Allergy to 5-nitroimidazole drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119293052\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Male partners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5937603\">",
"      - Breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3045469\">",
"      HIV-positive women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Refractory cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5453\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5453|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/1/42014\" title=\"picture 1\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5453|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/29/39388\" title=\"table 1\">",
"      Clinical features of vaginitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=related_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1882="Management of pregnant women with prosthetic heart valves";
var content_f1_53_1882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of pregnant women with prosthetic heart valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1882/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Robyn A North, MBChB, PhD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/53/1882/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/53/1882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 16, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy presents a unique set of problems for women with prosthetic heart valves. These replacements may be mechanical or bioprosthetic (heterografts or homografts).",
"   </p>",
"   <p>",
"    Mechanical heart valves are associated with an increased incidence of thromboembolic events during pregnancy. Therapeutic anticoagulation throughout pregnancy is essential to reduce the risk of thromboembolic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1\">",
"     1",
"    </a>",
"    ], but given the absence of adequate prospective controlled trials, the preferred anticoagulant regimen is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Maternal and fetal complications associated with the different anticoagulant regimens in women with mechanical and prosthetic valves and management guidelines are reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anticoagulation during pregnancy for women with mechanical heart valves'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bioprosthetic valves typically do not require anticoagulation (unless there are other thromboembolic risk factors), but bioprostheses have a significantly higher incidence of valve failure than mechanical valves. This may be of particular concern for young women, who must consider the potential for future valve surgery if they have a bioprosthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=see_link\">",
"     \"Management of patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Structural failure of bioprosthetic valves'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Management of pregnant women with prosthetic heart valves, including anticoagulant therapy is discussed here. Antimicrobial prophylaxis in patients with prosthetic heart valves is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISKS OF PROSTHETIC VALVES IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic heart valves are associated with a variety of complications, including structural failure of the valve, infection, heart failure, thromboembolism, and bleeding due to anticoagulation. The overall incidence of complications in appropriately managed, nonpregnant patients with prosthetic valves is approximately 3 percent per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Structural failure of bioprosthetic valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 35 percent of heterograft prostheses and 10 to 20 percent of homograft prostheses fail within 10 to 15 years of implantation. Thus, women of childbearing age who have a biologic prosthesis are likely to require a second valve surgery during their lifetime. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of prosthetic heart valves\", section on 'Mechanical versus bioprosthetic valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bioprosthetic valve failure is generally due to one of two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leaflet degeneration, resulting in severe regurgitation",
"     </li>",
"     <li>",
"      Progressive valve calcification, leading to significant stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With regard to pregnancy, concerns have been raised that the normal increases in blood volume and cardiac output may accelerate deterioration of bioprosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .) Although some studies suggested that valve deterioration is accelerated during or shortly after pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], subsequent reports have not confirmed this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of pregnancy was evaluated in a natural history study of 232 young women with prosthetic valves of whom 73 had a bioprosthesis and 72 a homograft [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structural valve deterioration and valve loss were more common with bioprosthetic valves. The 10 year rate of valve loss (valve replacement or valve-related death) with bioprosthetic and homografts valves were 82 and 28 percent, respectively.",
"     </li>",
"     <li>",
"      The risk of valve deterioration was seven-fold greater for the mitral than the aortic or tricuspid site.",
"     </li>",
"     <li>",
"      Overall 10 year patient survival for those with bioprosthetic and homograft valves was 84 and 96 percent, respectively.",
"     </li>",
"     <li>",
"      Approximately 55 to 60 percent of the women in each of these groups had at least one pregnancy.",
"     </li>",
"     <li>",
"      The rate of valve loss was not higher for those who had completed a pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in another report of 237 women &le;35 years of age with bioprostheses; 52 of the women had 94 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/9\">",
"     9",
"    </a>",
"    ]. At 10 years, the pregnancy group did not have a significantly higher rate of structural valve deterioration (55 versus 46 percent) or valve-related mortality (8 versus 7 percent).",
"   </p>",
"   <p>",
"    Limited data are available on the durability of pulmonary autografts in pregnant women. There was no evidence of valve deterioration in two reports of 55 pregnancies in 29 women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Pulmonary autograft (Ross procedure)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased physiologic demands of pregnancy (increased blood volume and cardiac output) may result in the development or exacerbation of heart failure. The management of heart failure during pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1509810\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve thrombosis is potentially a life-threatening complication. The procoagulant state of pregnancy increases the risk of valve thrombus formation among women with mechanical valves.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The risk of valve thrombosis and thromboembolic events depends upon the type and location of the prosthetic valve, as well as a number of other clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/5\">",
"     5",
"    </a>",
"    ]. Mechanical prosthetic heart valves have a higher thromboembolic risk than bioprosthetic valves or homografts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/8\">",
"     8",
"    </a>",
"    ]. Women of childbearing age are likely to have newer generation mechanical valves, with a lower thromboembolic risk than older mechanical valves. Other factors that increase thromboembolic risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of a prior thromboembolic event",
"     </li>",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      Prosthesis in the mitral position",
"     </li>",
"     <li>",
"      Multiple prosthetic valves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All women with mechanical heart valves (regardless of valve type or site) should be treated with therapeutic anticoagulation throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of valve thrombosis in pregnancy appears to be increased with unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and, to a lesser degree, with low molecular weight heparin compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anticoagulation during pregnancy for women with mechanical heart valves'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of prosthetic heart valves\", section on 'Valve thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bioprosthetic valves, independent of position, do not usually require chronic anticoagulation unless other thromboembolic risk factors are present. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Anticoagulation during pregnancy for women with mechanical heart valves'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1509919\">",
"    <span class=\"h2\">",
"     Bleeding due to anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When therapeutic anticoagulation is required during pregnancy and post-partum, there is the risk of pregnancy-specific bleeding related to the placenta or to delivery. Antepartum hemorrhage (unexplained or due to placenta previa or abruption) appears to be increased in women with mechanical valves on therapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Post delivery, bleeding related to cesarean section as well as vaginal and perineal trauma may be increased. As such, detailed planning of anticoagulation management before, during, and after delivery is critical. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Delivery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1509993\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis in patients with prosthetic heart valves is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIOR TO CONCEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of childbearing age who have valvular heart disease should receive special counseling prior to becoming pregnant. In some cases, the consequences of longstanding valve disease (eg, left ventricular dysfunction or pulmonary hypertension), result in prohibitive risks and pregnancy should be avoided. However, many women with both native valve disease and prosthetic heart valves can safely complete a pregnancy with careful management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Native valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with compensated valvular disease can be advised to complete a pregnancy before considering surgery. (See appropriate topic reviews for the indications for intervention for the individual valve lesions).",
"   </p>",
"   <p>",
"    Management of valve disease in a young woman should, whenever possible, be discussed before conception, particularly in cases in which correction of the lesion might be indicated before pregnancy. Examples include mitral stenosis with a valve area &lt;1.5 cm",
"    <sup>",
"     2",
"    </sup>",
"    that is suitable for percutaneous mitral valvotomy and aortic stenosis with a valve area &lt;1.0 cm",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women of childbearing age who require valve replacement should understand the various therapeutic options and the associated risks of prosthetic valves, especially during pregnancy. Some women might favor a bioprosthesis, which does not require chronic anticoagulation, over a mechanical prosthesis. However, they should be advised about the limited durability of these valves and the approximate 80 percent likelihood that a second operation will eventually be necessary at 10 years. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Structural failure of bioprosthetic valves'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Women with mechanical prosthetic valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;As therapeutic anticoagulation is essential during pregnancy and the puerperium, preconception counseling should include an informed discussion about the maternal and fetal risks associated with available anticoagulation options. The patient should also be informed that the risk of life threatening thromboembolic events and a thrombotic stroke exists regardless of the anticoagulant regimen utilized. Discussion of these risks should be included in counseling patients about future plans, including whether to forgo pregnancy.",
"   </p>",
"   <p>",
"    Women should be advised to continue oral anticoagulation until they are pregnant because the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    embryopathy (defects in cartilage and bone) is low in the first six weeks of gestation. Women of reproductive age should closely monitor their menses and if delayed, undergo a prompt pregnancy test. If the plan is to use therapeutic low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) for at least the first trimester, a plan should be made as to how this will be arranged once pregnancy is confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulation during pregnancy\", section on 'Warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION DURING PREGNANCY FOR WOMEN WITH MECHANICAL HEART VALVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic anticoagulation is recommended in all pregnant women with mechanical prosthetic heart valves (primarily mechanical valves) to prevent valve thrombosis and thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .) The absence of any adequate randomized trials and the paucity of prospective cohort data make it difficult to offer definitive recommendations on the optimal anticoagulant regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appears to offer the best protection against thromboembolic complications in women with mechanical heart valves, it freely crosses the placenta and it is associated with both a characteristic embryopathy, and an increase in late fetal deaths and hemorrhagic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1,14,16\">",
"     1,14,16",
"    </a>",
"    ]. Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) and low molecular weight heparin (LMWH) do not cross the placenta, but require twice daily subcutaneous injections and are associated with higher rates of maternal valve thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The data on UFH and LMWHs are further confounded by the use of sub-therapeutic dose regimens or poor compliance in many (but not all) reported cases of valve thromboses or thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14,15,18\">",
"     14,15,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the improved pharmacokinetics and bioavailability, their reduced side effect profile, along with apparent lower rates of associated valve thrombosis, LMWH&rsquo;s are increasingly the preferred treatment modality over UFH in several countries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ]. UFH use is often confined to intravenous (IV) administration at times when rapid reversal of the anticoagulant effect may be required (eg, intrapartum). Increasing evidence suggests therapeutic LMWH may be an acceptable alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for many women as they balance the slightly higher level of thrombotic risk against improved fetal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510158\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of various anticoagulant regimens in pregnant women with mechanical prosthetic heart valves was illustrated in a systematic review of 28 studies that included 976 women with 1234 pregnancies from 1966 to 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14\">",
"     14",
"    </a>",
"    ]. In pregnant women with mechanical heart valves,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was associated with the lowest rates of maternal thromboembolic complications, including valve thrombosis (3.9 percent for warfarin alone, 9.2 percent for UFH in the first trimester followed by warfarin, and 25 percent when therapeutic dose UFH was used throughout pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The applicability of these findings to contemporary practice is uncertain. None of the studies were randomized, approximately 50 percent of the women had older cage and ball valves that are more thrombogenic, and only 7 percent had newer bileaflet valves. Overall, the data indicate that warfarin use is associated with a low risk of maternal thromboembolic complications, in the order of 2 to 4 percent.",
"   </p>",
"   <p>",
"    In contrast to the potential maternal benefit, there is a substantial increase in congenital fetal anomalies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, primarily when used in the first trimester of pregnancy. Warfarin exposure early in pregnancy can cause a specific embryopathy affecting cartilage and bone (chondromalacia punctata, with stippled epiphyses and nasal and limb hypoplasia). The estimated incidence is 5 to 10 percent, although reported ranges vary [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14,20-22\">",
"     14,20-22",
"    </a>",
"    ]. It is thought that the greatest risk of warfarin embryopathy is after six weeks. In one review, the risk of major anomalies was 4.8 percent when oral anticoagulant therapy was discontinued by eight weeks gestation as compared to 1.4 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/23\">",
"     23",
"    </a>",
"    ]. The major anomaly rate appeared to be higher among those receiving warfarin as compared to those taking other anticoagulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Fetal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    exposure after the first trimester appears to increase the risk of central nervous system defects, presumably from microhemorrhages in neuronal tissues; five case reports have described massive fetal intracranial hemorrhage associated with maternal warfarin use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulation during pregnancy\", section on 'Warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is associated with a high rate of late fetal loss. In one review, after exclusion of spontaneous abortions, 12 percent of the 596 pregnancies in a women taking warfarin throughout pregnancy ended in a fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14\">",
"     14",
"    </a>",
"    ]. More recent data report a similar high perinatal death rate associated with warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dose-dependent effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    on fetal embryopathy and fetal loss has been reported, with warfarin &le;5mg having lower rates of fetal complications than warfarin &gt;5mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The clinical relevance of these findings is limited since the dosing is adjusted to achieve adequate anticoagulation (as measured by the INR) for each patient with a mechanical valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) is a large molecule that does not cross the placenta and therefore does not carry the same risk of teratogenicity. Published data on the use of UFH throughout pregnancy in women with mechanical valves are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. There are more data regarding staged therapy, with the use of UFH in the first trimester, followed by oral anticoagulants (OACs) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/7,14,26-28\">",
"     7,14,26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H6#H6\">",
"     \"Anticoagulation during pregnancy\", section on 'Unfractionated heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the systematic review described above, valve thrombosis was more common in women treated with UFH throughout pregnancy than when UFH was used during the first trimester than in women who took OAC&rsquo;s throughout pregnancy (25 percent of 16, 9.2 percent of 229 versus 3.9 percent of 792 pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;Further comparisons with UFH are limited by the use of prophylactic rather than therapeutic dose UFH in some cases and uncertainty about the intensity of monitoring aPTT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/13,14,26\">",
"     13,14,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose subcutaneous or IV UFH (eg, mid-dose target aPTT at least two times control) may provide better protection against thromboembolism, but even with this approach, concerning rates of thromboembolic complications have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/13,28\">",
"     13,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UFH also causes bone loss with reduced bone mineral density (BMD) in many pregnant women and osteoporotic fractures in a smaller number of patients (2.2 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/29\">",
"     29",
"    </a>",
"    ]. Although recovery of BMD occurs postpartum after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is discontinued, it is unclear if recovery is complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H4#H4\">",
"     \"Drugs that affect bone metabolism\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMWH also does not cross the placenta, and has several advantages over UFH: It has a more predictable attainment of therapeutic levels of anticoagulation, appears to have less effect on bone, and is associated with less bleeding and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .) At maternal request, therapeutic dose LMWH is increasingly used in clinical practice as an alternative to OAC&rsquo;s in pregnant women with mechanical heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/2,15-19,30\">",
"     2,15-19,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When therapeutic LMWH is used, it is recommended that peak anti-factor Xa (four to six hours after subcutaneous injection) be measured at regular intervals and the LMWH dose adjusted accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The 2004 ACCP guidelines recommended a peak anti-Xa target of 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    and the 2008 ACCP guidelines similarly recommended adjusting the LMWH dose to achieve the manufacturer&rsquo;s peak anti-Xa levels (approximately 1",
"    <span class=\"nowrap\">",
"     U/mL)",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H18\">",
"     'ACCP guidelines'",
"    </a>",
"    below). The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend maintaining anti-Xa levels between 0.7 and 1.2U per mL (see",
"    <a class=\"local\" href=\"#H17\">",
"     'ACC/AHA guidelines'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In July 2002, the United States Food and Drug Administration issued a warning to the product labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , indicating that this product is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for thromboprophylaxis in pregnant women with prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/31\">",
"     31",
"    </a>",
"    ]. This warning was subsequently endorsed by the Committee on Obstetric Practice of the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/32\">",
"     32",
"    </a>",
"    ]. However, some experts, including a 2002 Consensus Report Panel and Scientific Roundtable in fetal-maternal medicine, the American College of Chest Physicians guidelines, and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association support maintaining LMWH as a treatment option in pregnant women with prosthetic heart valves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/2,4,33\">",
"     2,4,33",
"    </a>",
"    ]. The consensus panel concluded that prosthetic valve thrombosis in the above reports was related to underdosing or inadequate monitoring of LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials of LMWH use versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or UFH in pregnant women with mechanical heart valves. A review of early publications reporting LMWH use in pregnant women with mechanical heart valves (16 studies, 1996 to 2003) found thromboembolic complications occurred in 12.3 percent of 81 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/15\">",
"     15",
"    </a>",
"    ]. When only women who received therapeutic LMWH were included, thromboembolism occurred in one of 37 pregnancies (2.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/15\">",
"     15",
"    </a>",
"    ]. A second review raised concerns with a 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/34\">",
"     34",
"    </a>",
"    ] rate of thrombotic events in 76 pregnancies reported in 23 papers (1996-2005) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/34\">",
"     34",
"    </a>",
"    ]. Publication bias in part contributes to these rates, with the higher rate of thromboembolic events in the second review due to inclusion of a greater number of single case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/15,34\">",
"     15,34",
"    </a>",
"    ]. In several cases, thrombotic events were related to use of subtherapeutic doses of LMWH, suboptimal anti-Xa levels, and poor patient compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recent studies suggest the rate of thromboembolic events in pregnant women with mechanical valves may be lower when therapeutic LMWH is managed with intensive anti-Xa monitoring, followed by dose adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16-19,30\">",
"     16-19,30",
"    </a>",
"    ]. In these small cohorts, a total of 109 pregnancies treated with twice daily, dose-adjusted therapeutic LMWH have been reported. These include 14 pregnancies (13 pregnancies in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16\">",
"     16",
"    </a>",
"    ] plus one pregnancy in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/17\">",
"     17",
"    </a>",
"    ]) in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    was the predominant therapy. In the remaining 95 pregnancies, thromboembolic complications occurred in 9.5 percent of women with mechanical valves treated with therapeutic range LMWH. In eight of the nine pregnancies with thromboembolic complications, there was subtherapeutic dosage, poor compliance, or low anti-Xa levels. There was one maternal death related to valve thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/30\">",
"     30",
"    </a>",
"    ]. These data suggest that if therapeutic LMWH with dose adjustment to maintain anti-Xa levels of 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     U/ml",
"    </span>",
"    is achieved, the risk of thromboembolic complications is low, probably less than 5 percent. When translated into clinical practice, however, the failure rate is likely to be in the order of 5 to 10 percent due to issues such as patient compliance.",
"   </p>",
"   <p>",
"    In later reports of therapeutic LMWH in women with mechanical heart valves, there appears to be an increased rate of antepartum and post partum bleeding complications. Of the 95 pregnancies summarized above, there were seven antepartum hemorrhages (secondary to placental abruption, placental praevia, or unexplained), nine post partum hemorrhages, four bleeds related to cesarean delivery, and four other hemorrhagic complications such as epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/16-19,30\">",
"     16-19,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in pregnant women with prosthetic heart valves are limited. However, aspirin has been studied in pregnant women with other indications, and its use appears safe [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/35\">",
"     35",
"    </a>",
"    ]. In selected nonpregnant patients with prosthetic heart valves, the addition of low dose aspirin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reduced thromboembolic complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Warfarin plus aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24052931\">",
"    <span class=\"h2\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct thrombin inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , should",
"    <strong>",
"     not",
"    </strong>",
"    be considered an alternative to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with prosthetic valves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during pregnancy. Adverse events have been observed in some animal studies, and safety data in pregnant women are lacking. Evidence is lacking on the efficacy and safety of dabigatran in patients with prosthetic valves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations from major societies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 focused update incorporated into the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    valve guidelines, the 2008 Eighth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy, and the 2007 European Society of Cardiology (ESC) guidelines on the management of valvular heart disease included recommendations concerning anticoagulation in women with mechanical prosthetic valves who become pregnant (",
"    <a class=\"graphic graphic_table graphicRef81671 \" href=\"UTD.htm?36/20/37196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines emphasize the following points [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation during pregnancy in women with mechanical prosthetic valves must ensure continuous, monitored, therapeutic anticoagulation.",
"     </li>",
"     <li>",
"      Pregnancy tests should be monitored in women on long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      who are planning a pregnancy to ensure prompt adjustment of anticoagulation therapy if needed.",
"     </li>",
"     <li>",
"      Women who elect to stop",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      between weeks 6 and 12 of gestation, to decrease the risk of fetal defects, should receive continuous IV, or dose adjusted subcutaneous (SQ) UFH or dose-adjusted SQ LMWH.",
"     </li>",
"     <li>",
"      The anticoagulant options up to week 36 of gestation include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , continuous IV UFH, dose adjusted SQ UFH, or dose adjusted SQ LMWH and the fetal and maternal risks with each should be fully discussed with the patient. Dose adjustment is recommended as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adjusted-dose LMWH twice daily to maintain an anti-Xa level between 0.7 and 1.2",
"      <span class=\"nowrap\">",
"       U/ml",
"      </span>",
"      4 hours after administration.",
"     </li>",
"     <li>",
"      UFH, initiated in high dose 17,500 to 20,000 U every 12 hours to achieve a six hour post dose aPTT at least twice control.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      to achieve an INR goal of 3.0 (range 2.5 to 3.5).",
"     </li>",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100 mg daily in the second and third trimester) is reasonable in addition to anticoagulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      should be discontinued and continuous IV UFH given starting two to three weeks before planned delivery. After delivery, UFH is resumed four to six hours after delivery and warfarin is restarted, in the absence of significant bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AHA guidelines emphasize that SQ",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing (UFH or LMWH) requires dose adjustment based on frequent monitoring of the level of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ACCP guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 Eighth American College of Chest Physicians (ACCP) guidelines recommend that the decision about anticoagulation management during pregnancy include an assessment of additional thromboembolic risk factors (such as valve type, position, and history of thromboembolism) and that the decision be strongly influenced by patient preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following four treatment options are recommended for anticoagulation in women who have a mechanical prosthetic valve. The first three recommendations place a high value on avoiding fetal risk while the fourth recommendation places equal value on avoiding maternal complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive adjusted-dose LMWH therapy throughout pregnancy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      initiated at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously every 12 hours). It is suggested that the dose be adjusted to achieve a four hour post-injection anti-Xa",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      level at the manufacturer's peak anti-Xa level (approximately 1.0",
"      <span class=\"nowrap\">",
"       U/mL).",
"      </span>",
"      (The prior 2004 ACCP guidelines had similarly recommended a peak anti-Xa level of 1.0 to 1.2",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/37\">",
"       37",
"      </a>",
"      ].)",
"     </li>",
"     <li>",
"      Aggressive adjusted-dose UFH throughout pregnancy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is administered subcutaneously every 12 hours in doses adjusted to keep the mid-interval aPTT at least twice the control, or an anti-Xa heparin level of 0.35 to 0.70",
"      <span class=\"nowrap\">",
"       U/mL.",
"      </span>",
"     </li>",
"     <li>",
"      UFH or LMWH therapy (using the above regimens) until the 13",
"      <sup>",
"       th",
"      </sup>",
"      week, a change to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      until close to delivery, and then restart UFH or LMWH therapy until delivery. Warfarin should not be given close to term in order to minimize the possibility of serious bleeding caused by the trauma of delivery to the anticoagulated fetus.",
"     </li>",
"     <li>",
"      In women judged to be at very high risk of thromboembolism in whom concerns exist about the efficacy and safety of UFH or LMWH as dosed above (eg, older generation prosthesis in the mitral position or history of thromboembolism),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is suggested throughout pregnancy with replacement by UFH or LMWH (as above) close to delivery, after a thorough discussion with the patient of the potential risks and benefits of this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, for pregnant women with prosthetic valves at high risk of thromboembolism, the addition of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     ESC guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important points from the 2007 ESC guidelines on the management of valvular heart disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 162",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      might be added to women deemed to be at high thromboembolic risk.",
"     </li>",
"     <li>",
"      Close collaboration among the patient, cardiologist, and obstetrician is required, and a thorough discussion of the risks and benefits of various anticoagulation strategies must be held.",
"     </li>",
"     <li>",
"      In a pregnant woman with a mechanical prosthesis, the choice of anticoagulant therapy during the first trimester should take into account the greater thromboembolic risk with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and the risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      embryopathy. The use of the latter during the first trimester is the safest regimen for the mother, and the risk of embryopathy is thought to be very low if the warfarin dose is &le;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1510158\">",
"       'Warfarin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"       \"Anticoagulation during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As much as possible, delivery should be planned and its modality discussed in close collaboration with the obstetricians and anesthetists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the ACCP, the ESC guidelines did not suggest LMWH as an alternative, due to concerns regarding increased risks of valve thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are insufficient to make a definitive recommendation, we suggest therapeutic dose-adjusted LMWH during the first trimester with frequent monitoring of anti-Xa levels. Whenever possible,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be ceased by the sixth week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of anticoagulation between weeks 12 and 36 is based on a discussion between the patient, the cardiologist, and the obstetrician. The options of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or LMWH are preferred, with dose adjustment to maintain therapeutic anticoagulation based on frequent blood test monitoring. If a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is preferred by the patient, but LMWH is unavailable, then adjusted dose, therapeutic IV UFH or SQ UGH may be used.",
"   </p>",
"   <p>",
"    Patients using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be switched to therapeutic dose LMWH or UFH at about week 36 of gestation, in anticipation of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1511146\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF VALVE THROMBOSIS DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with the management of valve thrombosis in pregnant women is limited. Controlled data do not exist and published reports are mostly from case series.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    may be considered for small, nonobstructive thrombi. However, for obstructive valve thrombosis, the treatment options are surgical thrombectomy and thrombolysis, both of which carry substantial fetal and maternal risks.",
"   </p>",
"   <p>",
"    In a series of 10 women treated for 12 episodes of valve thrombosis with surgery (four cases), thrombolysis (seven cases), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (one case), the following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the surgical group, there was one maternal death and one additional fetal death.",
"     </li>",
"     <li>",
"      In the thrombolysis group, there were two maternal deaths, one bleeding event requiring surgical drainage, but no fetal mortality in the surviving women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are reports of both cardiac surgery and thrombolysis in pregnant women involving larger numbers of patients with a variety of conditions. Even in these diverse case series, patient numbers are still small and no direct comparisons exist.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of published reports of cardiac surgery during pregnancy included a total of 70 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/40\">",
"       40",
"      </a>",
"      ]. Perioperative maternal and fetal mortality were 6 and 30 percent, respectively.",
"     </li>",
"     <li>",
"      A review of thrombolysis during pregnancy included 172 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/41\">",
"       41",
"      </a>",
"      ]. Maternal mortality, hemorrhagic complications, and fetal mortality rates were 1.2, 8, and 5.8 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data should be interpreted with caution, since both of these series included patients treated for a variety of conditions at a number of centers over an extended period of time (12 years for the surgical series and 34 years for thrombolysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, delivery should be planned, and its modality discussed in close collaboration with the obstetricians, hematologists, and anesthetists [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/42\">",
"     42",
"    </a>",
"    ]. Vaginal delivery is preferred in most cases, and cesarean delivery should be reserved for specific obstetrical indications or significant cardiovascular disease that places the woman at additional risk during labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Change in anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risks of maternal and fetal hemorrhage, the following changes in anticoagulant therapy should be made as a woman approaches the time for delivery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral anticoagulants should be switched to LMWH or UFH, no later than 36 weeks, with dosing and monitoring as recommended for women treated with these drugs throughout pregnancy.",
"     </li>",
"     <li>",
"      Women treated with LMWH or SQ UFH should be switched to IV UFH at least 36 hours prior to the induction of labor or cesarean delivery, in order to provide tighter control of anticoagulation throughout the peripartum period.",
"     </li>",
"     <li>",
"      IV UFH should be discontinued four to six hours prior to anticipated delivery, and should be restarted four to six hours after delivery at a low infusion rate (500",
"      <span class=\"nowrap\">",
"       u/h)",
"      </span>",
"      if there are no bleeding complications. Depending on the clinical circumstances, the IV UFH dose should be increased back to therapeutic levels over 24 to 72 hours.",
"     </li>",
"     <li>",
"      Cessation of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in the week prior to planned delivery should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Urgent delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;On rare occasions, urgent delivery is necessary for a woman with a mechanical valve while she is still receiving therapeutic anticoagulation. Life-threatening maternal hemorrhage can occur in this setting, but the risk of hemorrhage must be balanced against the potentially catastrophic risk of valve thrombosis if anticoagulation is reversed. (See",
"    <a class=\"local\" href=\"#H1509810\">",
"     'Thromboembolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because the likelihood of serious hemorrhagic and thromboembolic complications cannot be accurately quantified, there are differing opinions regarding when and how aggressively to reverse anticoagulation. Full reversal of anticoagulation is not necessary for either vaginal or cesarean delivery. Partial reversal may be indicated (eg, target INR of approximately 2.0), particularly if the patient is overanticoagulated. On the other hand, full reversal is warranted in patients with life-threatening maternal hemorrhage.",
"   </p>",
"   <p>",
"    In a patient on UFH or LMWH, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the woman is on IV UFH and time allows, the discontinuation of therapy and a delay of four to six hours should allow delivery without protamine.",
"     </li>",
"     <li>",
"      Vaginal delivery is preferred unless there are obstetric indications for cesarean delivery.",
"     </li>",
"     <li>",
"      If emergent delivery is necessary, protamine should be considered, bearing in mind that protamine will only partially reverse the anticoagulant effect of LMWH. The dose of protamine should be discussed with a hematologist, if available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H33#H33\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Bleeding and protamine reversal'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a patient on OAC&rsquo;s with an elevated INR (therapeutic or supratherapeutic) at the time of an urgent delivery, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because the fetus is also therapeutically anticoagulated, cesarean delivery is preferred to reduce risks of fetal trauma and hemorrhage.",
"     </li>",
"     <li>",
"      If time allows, delay",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      administration of small doses of vitamin K to a target INR of 2.0 should permit safe cesarean delivery.",
"     </li>",
"     <li>",
"      If emergent delivery is necessary, fresh frozen plasma should be administered prior to cesarean delivery in sufficient amount to reach a target INR of 2.0 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Depending upon timing and dose, the administration of vitamin K to the mother prior to delivery can also reverse the effect of OAC&rsquo;s in the fetus and therefore reduce the risk of fetal hemorrhage. If the mother was not fully reversed at the time of delivery, the newborn may be given FFP and vitamin K.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of significant bleeding, anticoagulation should be resumed shortly after delivery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV UFH or SQ LMWH should be resumed four to six hours after delivery at a prophylactic dose, gradually increasing the dose to achieve therapeutic anticoagulation over 24 to 72 hours. Some clinicians have raised concern that overlap of therapeutic dose LMWH with the recommenced",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , especially after cesarean section, may contribute to postpartum bleeding complications. Use of IV UFH post partum may allow more rigorous control of anticoagulation.",
"     </li>",
"     <li>",
"      After an uncomplicated vaginal delivery, OAC&rsquo;s can be resumed the same day. If the woman has had a caesarean section this should be delayed for one to two days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    can be discontinued once the INR is in the therapeutic range, although standard anticoagulation guidelines suggest continuing heparin until the INR has been therapeutic for 24 to 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations relate to the management of pregnant women with prosthetic heart valves.",
"   </p>",
"   <p>",
"    Management of pregnant women with prosthetic valves requires special clinical expertise and collaborative management by the cardiologist and obstetrician. Referral to a maternal-fetal medicine specialist is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with mechanical heart valves, continuous therapeutic anticoagulation is essential throughout pregnancy. The anticoagulant dose must be adjusted based upon frequent monitoring with the appropriate blood test. The major concern with use of SQ UFH or LMWH dosing during pregnancy is the difficulty in achieving and maintaining continuous therapeutic anticoagulation. Subcutaneous LMWH has a more predictable anticoagulant effect than UFH and data suggests that LMWH has a lower rate of valve thrombosis than SQ UFH.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    anticoagulation is safer for the mother but is associated with increased risks for the fetus.",
"   </p>",
"   <p>",
"    When selecting an anticoagulation regimen for a pregnant woman with a mechanical prosthetic heart valve, we agree with the following general recommendations emphasized in the 2005 ESC guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women should be informed fully about the importance of therapeutic anticoagulation throughout pregnancy.",
"     </li>",
"     <li>",
"      Maternal and fetal risks associated with each anticoagulant regimen should be reviewed in detail.",
"     </li>",
"     <li>",
"      Women should participate in the decision about which regimen to choose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data are insufficient to make a definitive recommendation on the specific anticoagulant to use before the 36",
"    <sup>",
"     th",
"    </sup>",
"    week, we suggest the following approach in order to balance fetal teratogenic risk and maternal thromboembolic risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staged therapy, in the following sequence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Anticoagulation during pregnancy for women with mechanical heart valves'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      During the first trimester LMWH, or second line UFH, initiated before the sixth week of gestation, with the dose adjusted to achieve the manufacturer's peak anti-Xa level (approximately 1.0",
"      <span class=\"nowrap\">",
"       U/mL)",
"      </span>",
"      at 4 hours after subcutaneous injection of LMWH,",
"      <strong>",
"       or",
"      </strong>",
"      mid-dose aPTT at least twice control measured at least weekly with UFH. Given the more predictable anticoagulant effects of LMWH, LMWH is preferred to UFH.",
"     </li>",
"     <li>",
"      The choice of anticoagulation between weeks 12 and 36 is based on discussion between the patient, cardiologist, and obstetrician. The preferred options are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or LMWH. Warfarin is dose adjusted to maintain an INR of 2.5 to 3.5, measured at least every two weeks, and is associated with the lowest risk of maternal thromboembolic complications. If LMWH is used, it should be administered subcutaneously twice daily at a therapeutic dose, with dose adjustment to maintain four hour post dose anti-Xa levels at approximately 1.0",
"      <span class=\"nowrap\">",
"       U/mL.",
"      </span>",
"      Ensuring patient compliance with LMWH and monitoring is critical.",
"     </li>",
"     <li>",
"      LMWH or UFH from the 36",
"      <sup>",
"       th",
"      </sup>",
"      week until delivery, with the dose adjusted to achieve the manufacturer's peak anti-Xa level (approximately 1.0",
"      <span class=\"nowrap\">",
"       U/mL)",
"      </span>",
"      at four hours after subcutaneous injection of LMWH, or aPTT at least twice control measured at least weekly with UFH. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Change in anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These parameters are generally consistent with those outlined in the 2008 ACCP guidelines. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'ACCP guidelines'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'ACC/AHA guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, given the limits of available data and the challenging balance of maternal and fetal risks, some physicians and patients will prefer alternative strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to the risk of valve thrombosis, some physicians and patients prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      throughout pregnancy, particularly in women with a high thromboembolic risk. Warfarin may also be preferred if the dose requirement is &le;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      which, as described above, appears to be associated with a lower risk of fetal complications [",
"      <a class=\"abstract\" href=\"UTD.htm?1/53/1882/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. As in the staged regimen, warfarin should be converted to LMWH or UFH from the 36",
"      <sup>",
"       th",
"      </sup>",
"      week until delivery. (See",
"      <a class=\"local\" href=\"#H1510158\">",
"       'Warfarin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"       \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Due to the risk of embryopathy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      early in pregnancy, as well as a small risk of CNS abnormalities at any stage of pregnancy and increased late fetal losses, some physicians and patients may prefer to avoid warfarin entirely in favor of LMWH or UFH throughout pregnancy. (See",
"      <a class=\"local\" href=\"#H1510158\">",
"       'Warfarin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For LMWH and UFH, we recommend the dosing and monitoring strategies outlined in the 2008 ACCP guidelines, which are more aggressive than those used in the past and those suggested for other indications. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'ACCP guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous LMWH should be used in preference to subcutaneous UFH.",
"     </li>",
"     <li>",
"      Given the adverse effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      on bone mineral density, we suggest calcium supplementation (1.2",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      during pregnancy and postpartum for women taking heparin to insure that the recommended daily allowance is achieved (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      be added to any regimen in a patient at increased thromboembolic risk (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment of valve thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data are limited and overall outcomes are poor in cases of valve thrombosis during pregnancy. Both maternal and fetal mortality rates are high. As noted above, management options are surgery and thrombolytic therapy. (See",
"    <a class=\"local\" href=\"#H1511146\">",
"     'Management of valve thrombosis during pregnancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest surgery rather than thrombolytic therapy for thrombosis of left-sided valves, and thrombolytic therapy for right-sided valves. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H9#H9\">",
"       \"Complications of prosthetic heart valves\", section on 'Valve thrombosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management at the time of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery involves additional hemodynamic and hemorrhagic risks in a woman with a prosthetic heart valve. Due to a lack of relevant data and the impact of patient-specific variables, standard guidelines do not exist and management in each case should be individualized with input from the patient, her obstetrician, her cardiologist, and an anesthesiologist. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Delivery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To minimize the risks of maternal and fetal hemorrhage, we suggest the following changes in anticoagulant therapy as a woman approaches the time for delivery (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Change in anticoagulation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral anticoagulants should be switched to LMWH or UFH, usually no later than 36 weeks.",
"     </li>",
"     <li>",
"      Women treated with LMWH or SQ UFH should be switched to IV UFH at least 36 hours prior to the induction of labor or cesarean delivery.",
"     </li>",
"     <li>",
"      IV UFH should be discontinued four to six hours prior to anticipated delivery, and should be restarted at",
"      <span class=\"nowrap\">",
"       500u/hour",
"      </span>",
"      at four to six hours after delivery if there are no bleeding complications. IV UFH is then increased to achieve a therapeutic APTT by 24 to 72 hours postpartum, depending on the mode of delivery and clinical status of the woman. IV UFH is continued until",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      achieves a therapeutic INR.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      can be resumed the same day as delivery. If the woman has had a caesarean section this should be delayed for one to two days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On rare occasions, urgent delivery is necessary for a woman with a mechanical valve while she is still receiving therapeutic anticoagulation. Life-threatening maternal hemorrhage can occur in this setting, but this must be balanced against the potentially catastrophic risk of valve thrombosis if anticoagulation is reversed. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Urgent delivery'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/2\">",
"      Elkayam U, Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol 2005; 46:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/3\">",
"      Ginsberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2003; 163:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/4\">",
"      Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/5\">",
"      Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med 1996; 335:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/6\">",
"      Badduke BR, Jamieson WR, Miyagishima RT, et al. Pregnancy and childbearing in a population with biologic valvular prostheses. J Thorac Cardiovasc Surg 1991; 102:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/7\">",
"      Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994; 71:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/8\">",
"      North RA, Sadler L, Stewart AW, et al. Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation 1999; 99:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/9\">",
"      Jamieson WR, Miller DC, Akins CW, et al. Pregnancy and bioprostheses: influence on structural valve deterioration. Ann Thorac Surg 1995; 60:S282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/10\">",
"      Salazar E, Espinola N, Rom&aacute;n L, Casanova JM. Effect of pregnancy on the duration of bovine pericardial bioprostheses. Am Heart J 1999; 137:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/11\">",
"      Avila WS, Rossi EG, Grinberg M, Ramires JA. Influence of pregnancy after bioprosthetic valve replacement in young women: a prospective five-year study. J Heart Valve Dis 2002; 11:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/12\">",
"      Dore A, Somerville J. Pregnancy in patients with pulmonary autograft valve replacement. Eur Heart J 1997; 18:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/13\">",
"      Sadler L, McCowan L, White H, et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG 2000; 107:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/14\">",
"      Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/15\">",
"      Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004; 92:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/16\">",
"      McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG 2009; 116:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/17\">",
"      Quinn J, Von Klemperer K, Brooks R, et al. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Haematologica 2009; 94:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/18\">",
"      Abildgaard U, Sandset PM, Hammerstr&oslash;m J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res 2009; 124:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/19\">",
"      Saeed CR, Frank JB, Pravin M, et al. A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clin Appl Thromb Hemost 2011; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/20\">",
"      Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/21\">",
"      Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/22\">",
"      Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/23\">",
"      Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95:949.",
"     </a>",
"    </li>",
"    <li>",
"     Coumarin derivatives. www.reprotox.org (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/25\">",
"      Wainwright H, Beighton P. Warfarin embryopathy: fetal manifestations. Virchows Arch 2010; 457:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/26\">",
"      Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996; 27:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/27\">",
"      Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/28\">",
"      Meschengieser SS, Fondevila CG, Santarelli MT, Lazzari MA. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 1999; 82:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/29\">",
"      Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/30\">",
"      Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol 2009; 104:1259.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/SAFETY/2002/lovenox.htm (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/32\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol 2002; 100:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/33\">",
"      The Anticoagulation in Prosthetic Valves and Pregnancy Consensus Report Panel and Scientific Roundtable. Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Fetal-Maternal Medicine Consensus Reports 2002; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/34\">",
"      James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med 2006; 19:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/35\">",
"      Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; :CD004659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/36\">",
"      Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/37\">",
"      Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:627S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/38\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/39\">",
"      Sahnoun-Trabelsi I, Jimenez M, Choussat A, Roudaut R. [Prosthetic valve thrombosis in pregnancy. A single-center study of 12 cases]. Arch Mal Coeur Vaiss 2004; 97:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/40\">",
"      Weiss BM, von Segesser LK, Alon E, et al. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. Am J Obstet Gynecol 1998; 179:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/41\">",
"      Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995; 50:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/53/1882/abstract/42\">",
"      Butchart EG, Gohlke-B&auml;rwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8126 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1882=[""].join("\n");
var outline_f1_53_1882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISKS OF PROSTHETIC VALVES IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Structural failure of bioprosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1509810\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1509919\">",
"      Bleeding due to anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1509993\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIOR TO CONCEPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Native valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Women with mechanical prosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTICOAGULATION DURING PREGNANCY FOR WOMEN WITH MECHANICAL HEART VALVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1510158\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24052931\">",
"      Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations from major societies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ACCP guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - ESC guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1511146\">",
"      MANAGEMENT OF VALVE THROMBOSIS DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Change in anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Urgent delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment of valve thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management at the time of delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/20/37196\" title=\"table 1\">",
"      AC pregnancy mechanical valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15238?source=related_link\">",
"      Management of patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_53_1883="Oxidized LDL in atherosclerosis";
var content_f1_53_1883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Role of oxidized LDL in atherosclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Endothelial damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alteration in vascular tone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monocyte/macrophage recruitment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased uptake of LDL by macrophages, with foam cell formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction of growth factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased platelet aggregation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Formation of autoantibodies to oxidized LDL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1883=[""].join("\n");
var outline_f1_53_1883=null;
var title_f1_53_1884="Influences on tests for IDA";
var content_f1_53_1884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Confounding factors in laboratory tests for iron deficiency anemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected value in patients with iron deficiency anemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confounding factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin",
"       </td>",
"       <td>",
"        &lt;11 g/dL",
"       </td>",
"       <td>",
"        Viral infections may cause a transient decrease in hemoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mean corpuscular volume",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        Thalassemia trait; hemoglobin E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red cell distribution width",
"       </td>",
"       <td>",
"        &gt;15",
"       </td>",
"       <td>",
"        Infection or inflammation, hemolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythrocyte protoporphyrin",
"       </td>",
"       <td>",
"        &gt;70-80 &micro;g/dL",
"       </td>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total iron-binding capacity",
"       </td>",
"       <td>",
"        &gt;450 &micro;g/dL",
"       </td>",
"       <td>",
"        Liver disease, inflammation, or hemolysis may lower TIBC; pregnancy or hormonal contraceptives may increase TIBC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transferrin saturation",
"       </td>",
"       <td>",
"        &lt;12-15 percent",
"       </td>",
"       <td>",
"        Infection or inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum ferritin",
"       </td>",
"       <td>",
"        &lt;12 ng/mL",
"       </td>",
"       <td>",
"        Infection or inflammation; liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transferrin receptor",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased in high turnover states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum iron",
"       </td>",
"       <td>",
"        &lt;30 &micro;g/dL",
"       </td>",
"       <td>",
"        Diurnal variation; iron intake; infection or inflammation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1884=[""].join("\n");
var outline_f1_53_1884=null;
var title_f1_53_1885="Advantages and disadvantages of central vein approaches";
var content_f1_53_1885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of central vein approaches",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Approach",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External jugular",
"       </td>",
"       <td>",
"        <p>",
"         Superficial vessel that is often visible",
"        </p>",
"        <p>",
"         Coagulopathy not prohibitive",
"        </p>",
"        <p>",
"         Minimal risk of pneumothorax (especially with US guidance)",
"        </p>",
"        <p>",
"         Head-of-table access",
"        </p>",
"        <p>",
"         Prominent in elderly patients",
"        </p>",
"        <p>",
"         Rapid venous access",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Not ideal for prolonged venous access",
"        </p>",
"        <p>",
"         Poor landmarks in obese patients",
"        </p>",
"        <p>",
"         High rate of malposition",
"        </p>",
"        <p>",
"         Catheter may be difficult to thread",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Internal jugular",
"       </td>",
"       <td>",
"        <p>",
"         Minimal risk of pneumothorax (especially with US guidance)",
"        </p>",
"        <p>",
"         Head-of-table access",
"        </p>",
"        <p>",
"         Procedure-related bleeding amenable to direct pressure",
"        </p>",
"        <p>",
"         Lower failure rate with novice operator",
"        </p>",
"        <p>",
"         Excellent target using US guidance",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Not ideal for prolonged access",
"        </p>",
"        <p>",
"         Risk of carotid artery puncture",
"        </p>",
"        <p>",
"         Uncomfortable",
"        </p>",
"        <p>",
"         Dressings and catheter difficult to maintain",
"        </p>",
"        <p>",
"         Thoracic duct injury possible on left",
"        </p>",
"        <p>",
"         Poor landmarks in obese/edematous patients",
"        </p>",
"        <p>",
"         Potential access and maintenance issues with concomitant tracheostomy",
"        </p>",
"        <p>",
"         Vein prone to collapse with hypovolemia",
"        </p>",
"        <p>",
"         Difficult access during emergencies when airway control being established",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Subclavian",
"       </td>",
"       <td>",
"        <p>",
"         Easier to maintain dressings",
"        </p>",
"        <p>",
"         More comfortable for patient",
"        </p>",
"        <p>",
"         Better landmarks in obese patients",
"        </p>",
"        <p>",
"         Accessible when airway control is being established",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increased risk of pneumothorax",
"        </p>",
"        <p>",
"         Procedure-related bleeding less amenable to direct pressure",
"        </p>",
"        <p>",
"         Decreased success rate with inexperience",
"        </p>",
"        <p>",
"         Longer path from skin to vessel",
"        </p>",
"        <p>",
"         Catheter malposition more common (especially right SCV)",
"        </p>",
"        <p>",
"         Interference with chest compressions",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Femoral",
"       </td>",
"       <td>",
"        <p>",
"         Rapid access with high success rate",
"        </p>",
"        <p>",
"         Does not interfere with CPR",
"        </p>",
"        <p>",
"         Does not interfere with intubation",
"        </p>",
"        <p>",
"         No risk of pneumothorax",
"        </p>",
"        <p>",
"         Trendelenburg position not necessary during insertion",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed circulation of drugs during CPR",
"        </p>",
"        <p>",
"         Prevents patient mobilization",
"        </p>",
"        <p>",
"         Difficult to keep site sterile",
"        </p>",
"        <p>",
"         Difficult for PA catheter insertion",
"        </p>",
"        <p>",
"         Increased risk of iliofemoral thrombosis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: ultrasound; SCV: subclavian vein; CPR: cardiopulmonary resuscitation; PA: pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Factor P, Sznajder JI. Vascular cannulation. In: Principles of Critical Care, Hall JB, Schmidt GA, Wood LDH (Eds), McGraw-Hill, New York, 1992. Copyright 1992 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1885=[""].join("\n");
var outline_f1_53_1885=null;
var title_f1_53_1886="Contents: Non TB mycobacterial infections";
var content_f1_53_1886=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Non TB mycobacterial infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Non TB mycobacterial infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11045\">",
"           Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/7/39033\">",
"           Buruli ulcer (Mycobacterium ulcerans infection)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/33/24089\">",
"           Epidemiology of nontuberculous mycobacterial infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/35/5687\">",
"           Microbiology of nontuberculous mycobacteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/11/24759\">",
"           Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25288\">",
"           Pathogenesis of nontuberculous mycobacterial infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5530\">",
"           Rapidly growing mycobacterial infections in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38777\">",
"           Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leprosy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/43/18105\">",
"           Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/30/39401\">",
"           Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23305\">",
"           Treatment and prevention of leprosy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/24/2441\">",
"           Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/39/13946\">",
"           Treatment of osteomyelitis due to nontuberculous mycobacteria in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-4D90219B8C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_53_1886=[""].join("\n");
var outline_f1_53_1886=null;
var title_f1_53_1887="Lateral rectal ligaments";
var content_f1_53_1887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral rectal ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A. The upper rectum is mobilized laterally by identifying the lateral rectal ligaments. The ligaments contain the middle hemorrhoidal vessels.",
"    <br>",
"     Figure B. The lateral ligament is divided between two clamps and the pedicle secured with ligatures.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_53_1887=[""].join("\n");
var outline_f1_53_1887=null;
